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Brucellosis is a zoonosis caused by Brucella species. Brucellosis research in natural hosts is often precluded by
practical, economical and ethical reasons and mice are widely used. However, mice are not natural Brucella hosts
and the course of murine brucellosis depends on bacterial strain virulence, dose and inoculation route as well as
breed, genetic background, age, sex and physiological statu of mice. Therefore, meaningful experiments require a
definition of these variables. Brucella spleen replication profiles are highly reproducible and course in four phases: i),
onset or spleen colonization (first 48 h); ii), acute phase, from the third day to the time when bacteria reach
maximal numbers; iii), chronic steady phase, where bacterial numbers plateaus; and iv), chronic declining phase,
during which brucellae are eliminated. This pattern displays clear physiopathological signs and is sensitive to small
virulence variations, making possible to assess attenuation when fully virulent bacteria are used as controls. Similarly,
immunity studies using mice with known defects are possible. Mutations affecting INF-γ, TLR9, Myd88, Tγδ and TNF-β
favor Brucella replication; whereas IL-1β, IL-18, TLR4, TLR5, TLR2, NOD1, NOD2, GM-CSF, IL/17r, Rip2, TRIF, NK or Nramp1
deficiencies have no noticeable effects. Splenomegaly development is also useful: it correlates with IFN-γ and IL-12
levels and with Brucella strain virulence. The genetic background is also important: Brucella-resistant mice (C57BL) yield
lower splenic bacterial replication and less splenomegaly than susceptible breeds. When inoculum is increased, a
saturating dose above which bacterial numbers per organ do not augment, is reached. Unlike many gram-negative
bacteria, lethal doses are large (≥ 108 bacteria/mouse) and normally higher than the saturating dose. Persistence is a
useful virulence/attenuation index and is used in vaccine (Residual Virulence) quality control. Vaccine candidates are
also often tested in mice by determining splenic Brucella numbers after challenging with appropriate virulent brucellae
doses at precise post-vaccination times. Since most live or killed Brucella vaccines provide some protection in mice,
controls immunized with reference vaccines (S19 or Rev1) are critical. Finally, mice have been successfully used to
evaluate brucellosis therapies. It is concluded that, when used properly, the mouse is a valuable brucellosis model.* Correspondence: emoreno@medvet.una.ac.cr
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ReferencesIntroduction
The genus Brucella comprises at least eight species
named according to their preferred mammal hosts. Bru-
cella melitensis, Brucella abortus and Brucella suis are
the most economically important species and they pre-
ferentially infect goats and sheep, bovines and swine, re-
spectively [1]. Livestock is the source of human
infections, and brucellosis is a severe disease that affects
a considerable number of people in the world [1]. These
bacteria cause long lasting chronic infections, mainly col-
onizing the reticuloendothelial system and reproductive
organs [2,3], replicating in the internal milieu of tropho-
blasts, macrophages and dendritic cells [4]. Although
able to multiply in life-less media, Brucella organisms
are better described as facultative extracellular intracellu-
lar parasites [5].
For many years the pathophysiology of brucellosis was
investigated in humans and natural hosts [3,6-9]. How-
ever, experimentation in ruminants, humans and pri-
mates has economical and ethical concerns or is
precluded for practical reasons. Consequently, small la-
boratory animals are frequently employed as models in
brucellosis research. One of the first experimentalmodels was the chicken embryo [10]. Although this
model was useful for evaluating the intracellular multi-
plication of Brucella, it does not differentiate virulent
from attenuated strains. The rabbit has been used in pro-
tocols designed to study Brucella toxicity and hypersen-
sitivity, mainly because of its susceptibility to bacterial
endotoxins and toxins [11]. Due to practical reasons
related to size, management and cost, the rabbit has
never been widely used as a model in brucellosis,
although it is used to produce antibodies against Brucella
antigens [12]. Owing to their high susceptibility to
Brucella infections and similarities in reproducing
human pathology, the guinea pig was extensively used as
an experimental animal [13]. These rodents reproduce
the pulmonary, hepatic, spleen and genital lesions and
the hypersensitivity reactions observed in humans, and
match the different phases of the infection caused by
Brucella in natural hosts, including abortion [13-15].
Thus, the guinea pig is one of the best models and it is
still used for some immunological and vaccine studies
[16,17]. However, when large numbers of animals are ne-
cessary, guinea pigs become impractical for the same
reasons as rabbits. Other laboratory rodents such as rats,
hamsters and gerbils have been used sporadically [13].
The mouse (Mus musculus) has been the most widely
used brucellosis model. Mice were first used by Holth in
1911 for Brucella vaccine testing. Thereafter, mice were
used for the etiological confirmation of samples from
infected animals, to test virulence and for the evaluation
of the pathological lesions (see [18,19]). The results in
mice are not immediately applicable and transferable to
humans or to the target animal species. However, the
uncovering of a significant phenotype in mice using an
appropriate protocol gives useful information. With the
arrival of inbred, mutant, knockout and transgenic mice
and the understanding of their biology and immunology
[20,21], this rodent has become the standard model for
brucellosis research.
In this work we have reviewed the models of infection
by O-polysaccharide containing (smooth) Brucella spe-
cies and strains in mice. Although we have focused on
in vivo assays, we occasionally refer to ex vivo studies in
cells when they are relevant for understanding the biol-
ogy of smooth brucellae in mice. For reasons related to
the extent of the document, we have avoided reviewing
the infection models induced by the rough brucellae. For
a better understanding on the biological behavior of the
rough strains in mice, we suggest the work of González
et al. [22].
Infection models
The outcome of the infection in mice depends on the
virulence and dose of the Brucella strain, the route of in-
oculation, and on the breed, genetic background, age,
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studies in mice are devoted to investigate virulence,
pathogenicity, immunology and vaccine properties, it is
critical to include control groups inoculated with appro-
priate reference Brucella strains [23,24]. In the following
sections, we discuss the importance of these factors.Figure 1 Replication profiles of B. abortus in mice spleens. (A)
Spleen replication curves of virulent (2308 strain), vaccine-attenuated
(S19 strain) and non-virulent (bvrS mutant) B. abortus strains during
36 weeks after inoculation in CD-1 mice. The abscissas axis (time
after infection) of the inserted panel is expressed in logarithmic
scale, to allow a better understanding of the initial phases of
infection. The different phases of the infection (I, onset of infection;
II, acute phase; III, chronic steady phase; IV, chronic declining phase)
are depicted by the discontinuous vertical lines. (B) Spleen
replication curves of virulent B. abortus 2308 strain in susceptible
BALB/c and resistant C57BL/10 mice (adapted from [35], with
permission).The Brucella strains: replication patterns and related
effects
The affinity of some Brucella species for a particular
mammal host is well-known [1]. It is also notorious that
B. melitensis and some biovars of B. suis infect humans
more frequently and cause a more severe disease than B.
abortus [1]; though, these infectivity and virulence pat-
terns do not always reproduce in mice. For instance, in a
comparative study it was found that the order of viru-
lence in mice was B. melitensis H38 (biovar 1)>B. abor-
tus 2308 (biovar 1)>B. suis 1330 (biovar 1) [25].
Moreover, there are differences in the pathological be-
havior among biovars and strains of some virulent spe-
cies, and the virulence demonstrated for their target
hosts does not necessarily parallels that observed in mice
[25,26]. The appraisal of these issues becomes more
complicated when different Brucella strains are simul-
taneously inoculated for comparative purposes. In
addition to the eight recognized Brucella species and
several biotypes (and more in the “waiting list”), a large
number of bacterial mutants and constructs have been
developed and tested in the murine system. In general,
three different categories of Brucella strains may be dis-
tinguished in relation to pathogenicity, ability to multiply
and persist in mice: virulent, attenuated and avirulent.
Although most organs of the reticuloendothelial sys-
tem may become infected (depending upon the bacterial
dose), the spleen and liver are the most conspicuously
infected organs in mice. In these organs, virulent smooth
brucellae (e.g. B. abortus 2308 and 544, B. melitensis
16 M and H38, and B. suis 1330) show a very reprodu-
cible pattern that is clearly different from that of the
attenuated vaccines and the non-virulent brucellae. In
the initial phases, the numbers of CFU/organ are similar
in the liver and in the spleen, but the number of CFU/g
of organ is lower in liver (one to two logarithms). In sub-
sequent phases, the CFU are consistently lower in the
liver [27,28] and virulent brucellae are completely cleared
from this organ beyond 3–4 weeks post-infection (pi)
[29]. This pattern is somewhat different from that
observed in spleens (see Physiopathology). In splenecto-
mized mice, the liver becomes rapidly colonized [15]. It
seems therefore, that the higher Brucella colonization of
the spleen during the chronic phases guards the liver
from a profound inflammation [15]. Due to this, liver is
seldom used for estimating the number of CFU, and thespleen is the preferred target organ to study Brucella
infections in mice.
The enumeration of bacteria in spleen (expressed as
the mean± SD of individual Log10 CFU/spleen or Log10
CFU/g of spleen; Figure 1) provides highly reproducible
replication profiles. The lapse of the different infection
phases (Figure 1) may vary depending upon the inocula-
tion protocol. Nevertheless, at the optimal dose of infec-
tion (see below) a consistent replication profile for the
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range [29]. In the understanding that infection with viru-
lent Brucella (at standard doses, see below) is a continu-
ous process and that delimitations are not clear cut, this
replication profile can be divided into four different
phases (Figure 1A): i) the onset of the infection, marked
by colonization during the first 48 h pi; ii) the acute
phase, extending from the 3rd day to the time when CFU
reach their maximum, generally between weeks 2 and 3;
iii) the chronic steady phase, that corresponds to the
CFU plateau, commonly lasting 8–11 weeks; and iv) the
chronic declining phase, at which there is a slow elimin-
ation of the bacteria that may last beyond 36 weeks. The
span of these phases may vary depending upon the bac-
terial dose, route, mouse strain and age [30]. Generally,
experiments in mice are not prolonged more than 3–
4 months and, therefore, data on the Brucella persistence
in these animals after this period are scarce. It has been
documented that Brucella organisms may still be recov-
ered from the spleen and lymph nodes of mice after
6 months of infection [25,31], suggesting that virulent
Brucella might remain in mice for life. Although some
quantitative variations have been observed, the spleen
replication patterns of virulent strains follow similar kin-
etics [24,25]. Fully avirulent strains (e.g. B. abortus bvrS
mutant; Figure 1A) are unable to multiply or persist, re-
gardless of the dose. In contrast, attenuated strains (e.g.
S19 and Rev1) can multiply at the levels of the virulent
strains at the early phases (Figure 1A) but persist for
shorter times, even when inoculated at large doses (e.g.
108 CFU/animal) [31]. The degree to which attenuated
bacteria are able to persist is the basis of the recom-
mended Residual Virulence quality control of anti-Bru-
cella vaccines [16]. It is expressed as the Recovery Time
50 (RT50), i.e. the time (in weeks) at which the bacter-
ium is eliminated from the spleens in half of vaccinated
mice. Used in this way, the murine model has demon-
strated its usefulness to detect batches of poor immuno-
genic reference vaccines [32-34].
The course of Brucella infections induced by attenuated
strains, such as vaccines S19 and Rev1, or non-virulent
mutants, such as VirB or BvrS [36,37], is radically shor-
tened and modified (Figure 1A). Similarly, the replication
profiles in knockout or mutant mice may vary according
to the defect displayed by the corresponding mouse strain
(Table 1). In the case of vaccine S19 (which shows a con-
spicuous Residual Virulence), the replication kinetics in
the spleen follows a rapid increase that peaks between
weeks 1 and 3, and then decreases steadily at approxi-
mately one logarithm per week [23,24]. Nonetheless, this
vaccine may still be recovered from spleens 8 to 12 weeks
pi. The replication profile of vaccine Rev1 shows some
differences with respect to that of S19. In general, Rev1
does not display the rapid increase demonstrated by S19,declines more slowly, and is still present after 8 to
12 weeks [33]. As stated above, non-virulent strains do
not multiply or increase in the initial phases of the infec-
tion, and then decline very fast (Figure 1A) being elimi-
nated from the spleen and the liver between the 2nd and
7th week [37,38].
Simultaneously with bacterial replication, there is swel-
ling of the spleen (Figure 2) and liver as well as draining
through lymphatics from the site of the infection (see
Physiopathology). The enlargement of the spleen is char-
acterized by a weight peak (e.g. ≥ 400 mg) evident from
weeks 3 to 16 (Figure 2A). This enlargement is a conse-
quence of inflammation [25] and it depends on the Bru-
cella dose and virulence [64], as well as on the immune
status and genetic background of the mice [50,53,65-67]
(see Physiopathology). For example, B. melitensis H38
induces an intense splenic enlargement that generally
surpasses that induced by other strains such as B. meli-
tensis 16 M, B. suis 1330 or B. abortus 544. Attenuated
S19 vaccine induces a characteristic peak of splenomeg-
aly that occurs close to 2 weeks after inoculation and
that, depending on the dose, may exceed that of B. abor-
tus 2308 or 544. However, while in S19 infected mice the
weight of the spleen rapidly decreases, the spleen of mice
inoculated with virulent Brucella keeps increasing up to
the end of the chronic steady phase (Figure 1B). Finally,
killed Brucella or non-virulent strains (e.g. B. abortus
BvrR/BvrS or VirB mutants) barely cause an increase in
spleen size, even when injected in very large quantities
(e.g. > 5 × 107/mouse) [68]. This corresponds to a gen-
eral phenomenon linked to the rapid removal and killing
of non-virulent strains by professional phagocytes.
Quality control of the Brucella strains is of paramount
importance. In addition to its tendency to dissociate into
rough forms [1,70], smooth brucellae are prone to be-
come attenuated upon storage at 4°C, after subculturing,
or in old or prolonged cultures without showing appre-
ciable biochemical or bacteriological modifications [32].
In vitro passages should be reduced to a minimum, and
the original strain kept for comparison. To rule out at-
tenuation as much as possible, it is recommended that
the Brucella strain be expanded only once, and then fro-
zen at −80°C or in liquid nitrogen until used. When
expanded, these frozen stocks should maintain the
expected parameters of the strain and pass at least one
additional test in macrophages: non-opsonized smooth
virulent brucellae multiply in non-activated macrophages
(e.g. RAW 264.7, J774, human monocytes or bone mar-
row derived) and show a characteristic replication curve
[66]. This profile often shows a 0.5 to 1.5 logarithm drop
during the first 12 to 15 h, and then steadily levels up
and increases 1 to 2 logs after 24 to 48 h. If the Brucella
strain keeps a steady state after the critical period of
12 h (as it is the case of B. abortus S19) or drops quickly
Table 1 Replication and persistence of smooth virulent Brucella in mutant and knockout mice strains
Test mouse strain Phenotypic defect Reference
mouse strain
Brucella spleen CFU
increase and persistence
relative to mouse reference straina
References
Early before
14 days
Late
after 15 days
CBA/H Inbred no specific defect BALB/c # " [39]
CBA/H Inbred no specific defect C57BL/10 " " [39]
CBA/NJ Inbred no specific defect BALB/c ↔ ↔ [40]
DBA2 Inbred no specific defect C57BL/6 " " [41,42]
CD-1 Outbreed Swiss mice BALB/c ↔ ↔ [40]
BALB/c Inbred no specific defect C3H/HeN ↔ ↔ [40]
BALB/c Inbred no specific defect C57BL/6 " " [39]
BALB/c Inbred no specific defect C57BL/10 " " [39]
BALB/c Inbred no specific defect C.CB (Nramp1r) # ↔ [43]
C57BL/10 Inbred no specific defect B10Br ↔ ↔ [39]
C57BL/6 (TLR9) CpG motifs recognition C57BL/6 " " [44,45]
BALB/c (TLR9) CpG motifs recognition BALB/c ↔ ↔ [46]
BALB/c (TLR4) LPS detection BALB/c ↔ ↔ [46]
BALB/c (TLR4) LPS detection BALB/c " ↔ [44]
C3H/HeJ (TLR4) LPS detection C3H/HePas " " [47]
C3H/HeJ (TLR4) LPS detection C3H/HeAu ↔ ↔ [48]
C3H/HeJ (TLR4) LPS detection C3H/Heb ↔ ↔ [41,42]
C3H/HeJ (TLR4) LPS detection C3H/HeN ↔ ↔ [40,49]
C3H/HeJ (TLR4) LPS detection BALB/c ↔ ↔ [40]
C57BL/6 (TLR4) LPS detection C57BL/6 ↔ ↔ [50]
C57BL/6 (TLR2) Lipoproteins detection and
peptidoglycan detection
C57BL/6 ↔ ↔ [47,50]
BALB/c (TLR2) Lipoproteins detection and
peptidoglycan detection
BALB/c ↔ " [46]
BALB/c (TLR2) Lipoproteins detection and
peptidoglycan detection
BALB/c ↔ ↔ [44]
C57BL/6 (TLR2/4) LPS and lipoproteins detection C57BL/6 ↔ ↔ [50]
BALB/c (TLR2/4) LPS and lipoproteins detection BALB/c " ↔ [44]
C57BL/6 (NOD1) muramyl peptides
meso-diaminopimelic acid
C57BL/6 ↔ ND [51]
C57BL/6 (NOD2) muramyl dipeptides C57BL/6 ↔ ND [51]
C57BL/6 (Myd88) Low proinflammatory response C57BL/6 " " [44,45,50]
C57BL/6 (TRIF) Low proinflammatory response C57BL/6 ↔ ↔ [44]
C57BL/6 (TRIF) Low proinflammatory response 129 Sv/Ev ND ↔ [44]
C57BL/10 (IRAK-4) Low proinflammatory response C57BL/6 " ↔ [52]
C57BL/6 (Rip2) NOD adaptor protein C57BL/6 ↔ ND [51]
C57BL/6 (gp91phox) Low respiratory burst in phagocytes C57BL/6 ↔ " [53]
C57BL/6 (iNOS) Low respiratory burst in phagocyte C57BL/6 " " [44]
C57BL/6 (iNOS) Low respiratory burst in phagocytes C57BL/6 ↔ " [53]
C57BL/6 (IL-12p40) Early differentiation of Th1 cells C57BL/6 ↔ " [53]
DBA/2j xC57BL/6
(iNOS/IL-12p40)
Early differentiation of Th1
cells and low respiratory burst
DBA/2j
xC57BL/6
↔ " [53]
DBA/2 J (ICSBP) Deficient in IL-12p40 and
low respiratory burst
C57BL/6 " " [53]
C57BL/6 xDBA/2 J
(iNOS/ICSBP)
Deficient in IL-12p40 and
low respiratory burst
C57BL/6 xDBA/2 J " " [53]
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Table 1 Replication and persistence of smooth virulent Brucella in mutant and knockout mice strains (Continued)
C57BL/6 (IRF-2) Deficient in NK cells and
dysregulation of IL-12p40
C57BL/6 # ↔ [53]
C57BL/6 (igh6) Affects B cells C57BL/6 ↔ ↔/# [54]
C57BL/6 (igh6) Affects B cells C57BL/6 # # [55]
BALB/c (jh) Affects B cells BALB/c # # [55]
C57BL/6 (rag-1) Affects B and T cells C57BL/6 ↔ ↔ [54]
C57BL/6 (Cd4) Affects CD4 T cells C57BL/6 ↔ # [54]
C57BL/6 (Aβ) Affects CD4 T cells C57BL/6 # ↔ [56]
C57BL/6 (Aβ) Affects CD4 T cells C57BL/6 ↔ ↔ [55]
C57BL/6 (Pfp) Affects Restriction of Tc
mediated killing
C57BL/6 " ↔ [57]
C57BL/6 (β2m) Affects CD8 T cells C57BL/6 " " [56]
C57BL/6 (β2m) Affects CD8 T cells C57BL/6 ↔ ↔ [54]
C57BL/6 (β2m) Affects CD8 T cells C57BL/6 " ↔ [57]
C57BL/6 (β2m) Affects CD8 T cells C57BL/6 ↔ # [55]
C57BL/6 (IL12/β2m) Affects CD8 T cells and
early differentiation of Th1 cells
C57BL/6 " " [58]
C57BL/6 (nu/nu) Lack thymus derived T cells C57BL/6 # " [59]
BALB/c (ifng) Absence of IFN-γ BALB/c ↔ " Dead [57]
C57BL/6 (ifng) Absence of IFN-γ production C57BL/6 " " [44,54,58]
C57BL/6 (ifng) Absence of IFN-γ production C57BL/6 ↔ " Dead [57]
C57BL/6 (ifng) Absence of IFN-γ production C57BL/6 ↔ " [55]
C57BL/6 (ifng) Absence of IFN-γ production C57BL/6 " ND [60]
C57BL/6 (IRF-1) CD8 T and NK cells
dysregulation of IL-12p40
low respiratory burst
C57BL/6 " " Dead [53]
BALB/c (infar1) More susceptible to viral
Infections. Affects NK
BALB/c ↔ ↔ [61]
C57BL/6 (INFαβR) More susceptible to viral
Infections. Affects NK
129 Sv/Ev ND # [62]
C57BL/6 (TCRδ) Absence of Tγδ cells C57BL/6 " ↔ [60]
C57BL/6 (GM-CSF) Higher lung infection
Defective alveolar macrophages
C57BL/6 ↔ ↔ [60]
C57BL/6 (IL-17Rα) Defective in PMN recruitment
and PMN activity
C57BL/6 ↔ ND [60]
C57BL/6 (IL-1β) Low proinflammatory response C57BL/6 ↔ ↔ [50]
C57BL/6 (IL-18) Early activation of NK and Th1
cells
C57BL/6 ↔ ↔ [50]
C57BL/6 (IL-1βx IL-18) Low proinflammatory response and
recruitment of NK and Th1 cells
C57BL/6 ↔ ↔ [50]
C57BL/10 (TNF-α) Low proinflammatory response C57BL/10 " ND [63]
Brucella susceptibility order: CBA/H>CBA/NJ=CD-1=BALB/c=C3H/HeN=C3H/HeJ>C57BL/10=C57BL/6≥B10Br.
a (") Significantly higher numbers of CFU in spleen than in controls; (#) significantly lower numbers of CFU in spleen than in controls; (↔) no significant number of
CFU in spleen in relation to the controls; ND, not done.
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attenuated or non-virulent. Alternatively, the macrophages
may have been activated (e.g. endotoxin in the culture
media), increasing their bactericidal abilities [66]. Once the
Brucella strain has passed this test, the stored aliquots of
the same stock shall be expanded and assayed in mice. In-
deed, it may happen that some strains showing the ad-
equate profile in macrophages fail to display a virulentprofile in mice and are thus attenuated. This is the case of
some mutants that, nevertheless, pass the multiplication test
in macrophages [22,71]. One alternative procedure when
hesitating about the quality of a Brucella strain of known
virulence is to inoculate the bacterium into mice and then
recover the organisms from the spleen after 2 to 3 weeks
[37,72]. Once selection of the virulent phenotype has been
ensured, the isolate has to be handled as described above,
Figure 2 Spleen inflammation in mice infected with B. abortus.
(A) Evolution of the average of spleen weights (as an indicator of
inflammation) of CD-1 mice infected with virulent (2308 strain),
vaccine-attenuated (S19 strain) and non-virulent (bvrS mutant) B.
abortus strains during 25 weeks after inoculation. The abscissas axis
(time after infection) of the inserted panel is expressed in logarithmic
scale to allow a better understanding of spleen inflammation at the
initial phases of infection. (B) Comparison of spleen size (left) and
histological transversal sections stained with hematoxylin-eosine of
normal spleen (upper panel) and B. abortus 2308 infected spleen, after
8 weeks pi (lower panel). Notice that the proportion between white
pulp/red pulp in the normal spleen is close to 1/1, while in the
infected spleen is close to 1/4. The histological section of normal
mouse is from Dr Frank Voelker, Flagship Biosciences, with permission
of Steve Pots Charting A New Course in Tissue Analysis [69].
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of infected mice [73].
Attenuated and non-virulent Brucella mutants present a
particularly difficult problem because stocks of these strains
in different laboratories frequently come from serial pas-
sages in vitro. This problem is exemplified by the differ-
ences in Residual Virulence found for various lots of
vaccines [16,32,33]. A drawback of vaccine Rev1 is its ten-
dency to dissociate from smooth to rough organisms. This
event has a profound negative effect on the immunogenicity
and Residual Virulence and efficacy, since rough bacteria
are highly attenuated [32,33]. The simultaneous presence oflarge and small colonies (evidenced only after 4 days cul-
ture) is a common change observed in S19 vaccines stocks
that may be related to virulence differences in mice [33].
Similarly, when making mutants by genetic manipulation, a
number of passages (frequently in the presence of antibio-
tics) is necessary, and these steps bias the selection in favor
of bacteria that grow preferentially in vitro and that may
introduce further attenuation not associated with the spe-
cific genetic defect studied. Therefore, it is always recom-
mended to balance these studies with the use of
complemented mutant strains, even if this method does not
necessarily restore the levels of the original in vivo
behavior [37].
The above-described Brucella replication profiles can
be expressed either as log10 CFU/organ or as log10 CFU/g
of organ. However, in some cases the CFU/organ may give
statistical significant differences, whereas the normalized
CFU/g of organ values may erase this statistical signifi-
cance. Expressing the CFU/gram, while correcting for
individual variations due to inflammatory responses, elimi-
nates information on the absolute bacterial numbers
recovered, and then the CFU values are lower. It is thus
better to express the CFU per organ. One concern about
the latter method is that it assumes that all mice have
closely similar spleen weights. If deemed necessary be-
cause there are large differences in spleen weights, it is
possible to include the individual spleen weights and CFU/
organ in two “dot” graphics. In most cases, however, the
overall significance does not change.
Route of the infection
Mice are commonly infected intraperitoneally (i.p.) or
intravenously (i.v.) with doses ranging from 104 to
107 CFU/mouse in a volume of 0.2 to 0.05 mL. Both
routes infect 100 % of the mice and induce similar levels
of infection. However, the i.p. route is preferred: it is
technically simpler, admits larger volumes and, therefore,
it is less prone to inoculation errors. The i.p. route
results in higher bacterial counts and faster colonization
of the spleen than other organs [39,65,74]. On the other
hand, the i.v. route (commonly in the tail vein) promotes
a slightly faster and higher bacterial colonization of the
liver in relation to the spleen during the first 10 days, an
event that is reversed during the following 2 weeks and
then maintained throughout the infection period, up to
120 days or more [29]. Smooth brucellae are quickly
phagocytized by leukocytes following i.v. inoculation.
The same phenomenon is observed after i.p. infection
but with 1 to 3 h delay [14], suggesting that the bacteria
promptly reach the blood via the thoracic duct and prob-
ably through the peritoneal capillary system as well. No
matter if inoculated i.p. or i.v., bacteria are distributed
throughout the reticuloendothelial system and placenta
within the 1st week, and depending on the dose, they can
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[25,75,76]. The central nervous system of the adult nor-
mal mouse does not seem to be colonized when using
these routes, even at high doses [76]. Although strict ex-
perimentation concerning the presence of the bacterium
in the meninges has not been performed, the behavior of
infected mice does not suggest brain infection. It is strik-
ing that in contrast to what has been reported in
humans, dolphins and the fetuses of ungulates [77-79],
there are no reports on neurobrucellosis in other juvenile
or adult natural Brucella hosts, such as bovine, caprine
or ovine. However, since domestic animals are most
often culled upon evidence of the disease, this is an as-
pect that has not been studied in all its dimensions. Neu-
robrucellosis is quite an interesting syndrome because
the hematoencephalic barrier imposes several unique
conditions to the invading pathogen.
The subcutaneous (s.c.) inoculation, either in the back
zone or in the footpad of mice results in lower levels of
infection than the i.p. or i.v. routes [26,74,80,81]. This ef-
fect may be due to local recruitment of bacteria at the
site of inoculation. The s.c. route in the back zone is
recommended for quality control of vaccines [16]. Inocu-
lation of Brucella suspensions (e.g. 105 to 106 CFU/
mouse in 0.05 mL) into the footpad causes local inflam-
mation; enhanced by the relatively large volume depos-
ited in a small area that induces tissue destruction and
the subsequent phagocytosis by resident leukocytes.
After footpad injection a spreading of the Brucella infec-
tion takes place through the lymphatics, favoring the
localization of the bacterium in the popliteal lymph node
[75,82-84]. At about 1 h pi, brucellae are already
detected in blood, spleen and liver, reaching a transient
plateau in these organs 6 h later [83,84]. Then, they can
extend to other organs [74]. The s.c. infection in the
back zone (e.g. 105–109 CFU/mouse) follows a similar
course as the footpad inoculation [74]. The s.c. inocula-
tion of B. abortus or B. melitensis rarely induces pus.
Nevertheless, depending on the bacterial dose and the
volume injected, a local granuloma formed by mono-
nuclear cells and neutrophils appears in the inoculation
site after several days. Vaccine Rev1 can induce encapsu-
lated local transient abscesses when inoculated by the s.
c. route. However, this only happens at very high doses
(≥ 108 CFU) and abscesses are of benign nature being
resolved in a few days/weeks [22], in parallel with what it
is observed in sheep inoculated by s.c. route with the
same strain [85].
The respiratory route of infection (through aerosols or
intranasal) has been considered by some authors as the
most natural route, and a source of laboratory accidents
and of potential bio-terrorism attacks [86,87]. Leaving
aside the inherent risks of this procedure, a precise as-
sessment of the CFU inoculated is more inexact thanwhen using other routes. The aerosol method requires
estimating the bacterial inocula within a respiratory
chamber by sacrificing a group of mice immediately after
exposure to the aerosol [86,87]. Moreover, simultaneous
infection trough conjunctival, nasal and oral mucosae
cannot be excluded during aerosol exposure, with the
ensuing problems in interpretation. The intranasal route
of infection displays similar problems because mice are
very good at sneezing, generating local aerosols. In any
case, these routes of inoculation induce an immediate in-
fection of the lungs, which is then distributed by blood
to the reticuloendothelial system [86-88]. Early in lung
infections, Brucella is present and replicates in alveolar
macrophages. Then, bacteria are disseminated to the
lung-draining mediastinal lymph nodes where they repli-
cate in both migratory dendritic cells and migratory al-
veolar macrophages. These last phagocytic cells seem to
be critical regulators of the early innate immune re-
sponse within the lungs [4].
The oral route by gavage has been used in mice attempt-
ing to reproduce human or experimental goat [89] infec-
tion after ingestion of contaminated dairy products with
Brucella [90-92]. However, the gastrointestinal route is
inefficacious to infect humans [7,93] and mice [91] with
Brucella. In addition to the challenges posed by the local
microbiota, epithelial layers and specific local immune
responses, the gastric acid pH and bile salts negatively
affect bacteria that, like brucellae, hardly or not at all grow
at pH below 5 and have outer membranes that are not
barriers to hydrophobic substances [94]. The difficulties in
infecting mice by this route may also be related to the
robust local resistance associated with the presence of
specialized Paneth cells in the intestinal tract. These cells
are rich in bactericidal substances that, together with the
strong acidic conditions, contribute to the gastrointestinal
barrier in mice [21]. Moreover, there are some technical
difficulties intrinsic to this route, and infection trough the
oral mucosa and the “digestive” or “intestinal” infec-
tion are very different issues [3]. To achieve infection
through gavage inoculation, very large numbers of Brucella
(≥ 1010 CFU/mouse) have to be placed in the oro-
esophageal cavity typically in 0.1 to 0.25 mL. Under these
conditions, the plastic tubing or ball needles used in gavage
are prone to deposit bacteria into the upper esophagus and
in the oral cavity. Consequently, infections via both oral
and throat mucous membranes are exceedingly difficult to
rule out. Even with those large doses, only a low proportion
of bacteria (1–2 %) translocate through gut cells, and are
distributed in the reticuloendothelial organs. After 8 h, the
bacteria may be recovered from the ileum, cecum and
colon and to a lesser extent from the spleen, liver, mesen-
teric lymph nodes and Peyer´s patches. As expected,
whereas in the intestine the numbers of bacteria decrease
over time, the numbers in the spleen, liver and lymph
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cating the high affinity of Brucella for the reticuloen-
dothelial system. A proportion of mice do not show
bacteria in the main target organs [91,92], consistent
with the idea that Brucella infection through the
gastrointestinal route is unfavorable. As an alternative
to gavage, large numbers of Brucella have been injected
into intestinal loops, favoring the internalization of signifi-
cant bacterial numbers by ileal Peyer´s patches dendritic
cells [95]. This procedure induces little inflammatory
response.
Infective dose
A myriad of bacterial doses have been used in experi-
mental murine brucellosis. Indeed, it is essential to deter-
mine the dose retrospectively by plating aliquots of the
inoculum [33,68]. To know how many live bacteria have
been inoculated is critical because, whereas live brucellae
predominantly induce a Th1 response [66], dead brucel-
lae have a tendency to induce T-independent responses
[96]. This precaution is even more relevant when differ-
ent Brucella strains are compared.
Brucella hardly induces mortality in mice and, therefore,
it is not commonly used as a criterion of virulence. Singer-
Brooks [19] performed a comprehensive study on the
effects of Brucella dose in mice. She observed that a larger
proportion of mice succumbed after i.p. injections of
massive doses of virulent smooth Brucella (> 4×108 CFU/
mouse), displaying obvious clinical signs. On the contrary,
doses lower than 107 CFU/mouse did not induce death or
relevant clinical symptoms. Nevertheless, these non-lethal
doses induced necrotic areas in the liver and spleen enlarge-
ment within the first 3 weeks pi. Perusal of the literature
shows that these observations have been repeatedly
confirmed.
The optimal dose of Brucella infection is defined as the
lower number of bacteria that infects the spleen of all mice
(between 20–23 grams) at consistent significant levels [97].
This optimal dose varies depending on the bacterial strain
and route of infection as well as on the genetic background
and physiological status of the mice. The optimal dose has
been determined only for classical brucellae [25,35,75,81] as
well as for some bacterial constructs [22,98]. When inocu-
lated at low doses (< 103 CFU/mouse), Brucella induces in-
consistent infections in mice, generating wide standard
deviations in CFU that complicate statistical interpretations.
Doses lower than 103 CFU/mouse do not produce gross
anatomical changes, despite the fact that some mice show
bacteria in several organs and tissues during the first weeks
[19]. In contrast, very high Brucella inocula (> 107 CFU/
mouse) cause saturation of the spleen, to the point that the
number of CFU per organ does not increase with respect to
the optimal dose. Although these large doses induce a
noticeable enlargement of the target organs (e.g. spleen andliver), distribution of Brucella in the reticuloendothelial
system barely changes [29]; however, other organs may be
also invaded [76]. If the mouse survives, the reduction of
Brucella numbers follows its course albeit with a more
protracted elimination time. B. abortus 2308 at i.p. doses
between 5×108 and 109 CFU/mouse kill almost 50 % of the
mice after 48 h, and 100 % before 1 week [48]. At these
large doses, clinical symptoms such tachypnea, lethargy,
piloerection, dehydration, and prostration were observed as
early as 8 h pi. Since larger doses of killed Brucella are non-
lethal, these symptoms relate to the massive organ invasion
by live bacteria [48]. High numbers of attenuated Brucella
(e.g. > 5×108 CFU), such as S19 or Rev1, seldom kill mice,
although they may induce some clinical symptoms [22].
A relevant effect observed when inoculating large
Brucella doses (e.g. > 5 × 107 CFU/mouse) is that blood
and cytokine profiles approach those induced by endo-
toxic bacteria like Salmonella [48]. This is an indication
that Brucella neither induces an obvious inhibitory ac-
tion on immune cells nor hampers the synthesis of
proinflammatory cytokines at the onset of the infection,
and that there is a threshold over which some molecules
carrying pathogen-associated molecular patterns may be
available to innate immunity receptors.
The mouse
Mice are highly resistant to brucellosis because they are
only killed by very large doses of virulent Brucella
[19,48]. However, mice seem more sensitive to brucel-
losis than rats, hamsters and rabbits [13,99]. Mice
infected with doses of virulent Brucella (e.g. B. abortus
2308) lower than 107 CFU/mouse, hardly show any
changes in behavior, or cachexia or wasting syndromes,
all signs induced by endotoxic bacteria [19,48]. Never-
theless, and depending on the mouse strain, Brucella can
cause long lasting infections that may extend throughout
the lifespan, accompanied by characteristic pathological
signs.
Resistant and susceptible mouse strains
All mouse breeds tested are susceptible to Brucella
[49,100], suggesting the inexistence of specific resistance
murine genes to brucellosis. However, some breeds seem
more resistant than others (Figure 1b and Table 1). The
best examples are the “susceptible” DBA2, C3H/He and
BALB/c strains and the “relatively resistant” C57BL/10
and C57BL/6 derived strains [35,39,41,42,101]. The
difference between these mouse strains is not related to
blood clearance rates or to the number of bacteria reach-
ing the spleen at the onset of the infection, which seem
similar. Moreover, the resistance displayed by C57BL
mice is not due to a stronger microbicidal activity of
macrophages or to any other early innate immunity
effector [102]. Rather, this resistance is manifested as
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oculation as well as dissimilar Th1 responses [103]. The
spleen and liver CFU during the plateau phase (1 to
10 weeks pi) are commonly about ten-fold lower in the
resistant C57BL strains (Figure 1B). In addition, the
C57BL mice show less splenomegaly. The central dif-
ference between resistant and susceptible mouse
strains seems to be the inability of the latter to
maintain the production of IFN-γ after the acute
phase, a phenomenon that extends throughout the
chronic steady phase up to at least the 6th week p.i.
[65,103]. As expected, this phenomenon is redundant
to other events, such as the recruitment and activa-
tion of immune cells [66,103]. A conspicuous differ-
ence between the BALB/c and C57BL/6 strains is the
lymphocyte/granulocyte proportion in blood, which is
close to 80/15 % in the former and to 90/9 % in the
latter [20], a phenotype that may be related to
Brucella clearance due to the regulatory action that
neutrophils can display over macrophages [4].
B. melitensis replicates similarly in macrophages
obtained from BALB/c and C57BL mice. Moreover,
both strains of mice share the “sensitive” form
(Nramp1s) of the Nramp1r (natural resistance-asso-
ciated macrophage protein) allele, which codes for a
membrane phospho-glycoprotein implicated in the
early activation of macrophages [43]. Unexpectedly,
during the 1st week after infection, the spleen and
liver of “sensitive” BALB/c contain less B. melitensis
CFU per organ than mice (e.g. C.CB) harboring the
resistant r1r allele form (Table 1). However, the
spleen and liver weights in the Nramp1r mice are
larger than in the Nramp1s mice, suggesting a more
profound inflammation. It is noteworthy that expres-
sing the results as CFU/gram of organ reduces the
difference between these two strains. The absence of
significant role of Nramp1s allele in brucellosis is
striking, since this gene is implicated in the resist-
ance/susceptibility to other intracellular bacteria
[104].
In spite of the quantitative differences, the Brucella
replication profiles in the sensitive and resistant mouse
strains follow a more or less parallel path [35,39]. This
means that the slope of the replication curves is very
similar in both strains (Figure 1B). Consequently, any
Brucella strain displaying a more negatively pronounced
slope must be considered attenuated, no matter whether
the bacterium was tested in the resistant or in the sensi-
tive mouse strain [22,37]. This parallelism between
mouse strains is also maintained when testing attenuated
brucellae [35,39]. Therefore, the differences in Brucella
replication between the sensitive and resistant mouse
strains should be interpreted in quantitative terms rather
than in multiplication kinetics.Mutant and knockout mice
Mice with defects or mutations influencing the innate
or/and adaptive immune responses may show significant
changes when infected with Brucella (Table 1). For in-
stance, athymic nude mice do not clear Brucella after
the acute phase [27,59], a time when cell mediated im-
mune response has fully developed in immunocompetent
mice [103]. During this period, nude mice develop
granuloma in the liver and persistent infections of the
biliary tract. In spite of this, the infection is not lethal (at
least in 3 months), possibly because of immune compen-
satory phenomena existing in these mice [59]. In fact,
nude mice seem to perform better in eliminating
Brucella during the onset and early acute phases of
infection. This suggests that the enhanced innate im-
mune response displayed by these mutant mice [27,59] is
able to partially control the infection, at least during this
period. Moreover, nude mice are capable to develop a
robust T-independent response against Brucella smooth
lipopolysaccharide (LPS) [105]. Since antibodies against
LPS are protective in murine brucellosis (Table 2), their
generation in nude mice may well exert some protection
at later times.
Virulent or attenuated Brucella extensively replicate in
mice deficient in INF-γ production, a cytokine required
to develop an adequate Th1 immune response (Table 1).
When infected, the INF-γ deficient mice show significant
clinical signs, such as cachexia and a severe splenomeg-
aly, with macrophages accounting for more than 75 % of
the spleen cells; these mice eventually die [118]. Simi-
larly, Brucella replicates extensively in knockout mice
defective in IFN-γ regulatory factor (IRF)-1 or in mice
displaying mutations in the IFN consensus sequence
binding protein (ICSBP), which are transcriptional
elements regulated by INF-γ [53]. Analogous to what has
been observed in the INF-γ deficient mice, Brucella (e.g.
> 5× 105 CFU/mouse) are lethal for IRF-1 mutant mice.
In these animals, not the spleen but the liver is the main
target organ [53]. Furthermore, whereas the liver shows
significant hepatitis and granuloma formation, the spleen
yields CFU numbers similar to those obtained in the
parental immunocompetent mice. Brucella also
replicates better at later times in mice defective in regu-
latory cytokine IL-12 (Table 1), involved in maturation of
T cells and necessary for the development of Th1 im-
mune responses [53].
Mutations in genes coding for IL-1β, IL-18, TLR5,
TLR2, NOD1, NOD2, GM-CSF, IL/17r, Rip2, TRIF or
type-1 INFr, all key factors of innate immune response,
have little or no effect on Brucella spleen replication
(Table 1). However, mutations disturbing TLR9, Myd88,
IRAK-4, Tγδ cells, or in the generation of TNF-α,
influence the clearance and favor Brucella replication
(Table 1). There is some controversy on the role of TLR4
Table 2 Effect on bacterial counts in mouse spleen (CFU) after passive transfer of antibodies, cells or cytokines at
different phases of smooth virulent Brucella infection
Treatment Administration of
treatment in relation
to the time of
infection
Main effect in infected mice Brucella CFU
in the spleena
References
Acute before
14 days
Chronic after
15 days
Rabbit anti-
Brucella
2 h, 16 h before
or 2 h after
Immune serum from
Brucella infected mice
directed against a variety
of different antigens
# # [106]
Murine anti-
Brucella
2 h, 16 h before
or 2 h after
Immune serum from
Brucella infected mice
directed against a variety
of different antigens
# # [84,98,107]
Anti-LPS 16 h before Immune murine sera
against Brucella LPS
# # [84]
Anti-O:9 16 h before Immune murine sera
against Yersinia
enterocolitica O:9. It
protects mice but to a
lesser extent than anti-Brucella
# # [84]
Anti-peptido-
glycan
16 h before Polyclonal immune sera
against peptidoglycan
protein complex,
probably contaminated with LPS
# # [84]
Mabs anti-O-
chain LPS
4 h before Several antibody isotypes
reacting against A, M and
C epitopes of the B.
abortus O chain of LPS
# # [35,108-110]
Mabs anti-
Omps
24 h before Against Omps of
molecular weight 10,
16.5, 19, 25–27, 31–34,
36–38 and 89
↔ ↔ [109]
Mab-anti-
Omp16
24 h before It induces lower
protection than anti- O
chain antibodies; IgG2a
isotype
# ND [109]
Mab-anti-
Omp25
24 h before It induces lower
protection than anti-O
chain antibodies; IgG2a
isotype
# ND [109]
Mab-anti-
Omp2b
4 h before Reacts against B. abortus
Omp2b, which generally
is not accessible in
smooth bacteria
↔ ND [35]
Mab-anti-
Omp31
24 h before It induces lower
protection than anti-O
chain LPS antibodies; IgG2a
isotype
# ND [109]
Spleen cells Same day as
infection
Protection was efficiently
transferred to naive mice
using spleen cells from
mice infected 5 or 12 weeks earlier
ND # [111]
Immune
Tcells
2 h after
infection
It gave similar protection
than CD8+ or CD4+ cells
passively transferred.
Immune cells from six
week infected mice.
Before 4 week there is no protection.
# ND [98,112]
Immune
CD4+T cells
2 h after
infection
It gave similar protection
than CD8+ cells passively
transferred. Immune cells
from six week infected
# ND [107]
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Table 2 Effect on bacterial counts in mouse spleen (CFU) after passive transfer of antibodies, cells or cytokines at
different phases of smooth virulent Brucella infection (Continued)
mice. Before 4 week there
is no protection
Immune
CD8+T cells
2 h after
infection
It gave similar protection
than CD4+ cells passively
transferred. Immune cells
from six week infected
mice. Before 4 week there
is no protection
# ND [107]
Serum
anti-Brucella and
T cells
2 h after
infection
Enhanced protection over
administration of just T
cells or Abs alone
# ND [107]
Immune
T cell+anti-
INF-γ
Anti- INF-γ 1day
before T cells
with challenge
It gave similar protection
than passively transferred T
cells
↔ ND [112]
Bovine Mø 1 day before
infection
Transferred to NK1.1
cell-depleted Rag-1−/−
mice
↔ ND [60]
Bovine
Mø+γδT cells
1 day before
infection
Transferred to NK1.1
cell-depleted Rag-1−/−
mice
# ND [60]
Bovine
Mø+CD4
T cells
1 day before
infection
Transferred to NK1.1
cell-depleted Rag-1−/−
mice
↔ ND [60]
INF-γ 1 day before
and 2 and 4 day
after
It Induces splenomegaly.
Mice show enhanced
peritoneal and splenic
macrophage bactericidal
activity
# ND [113]
IL-12 With the
infection and
every 3 days after
The levels of INF-γ
increase during the third
week of infection
↔ # [114]
IL-1α 4 h before CSF-1 increases in serum
during the first 12 h.
Colony forming cells
increase in the spleen,
mainly Mø and PMNs.
Thirty days after treatment,
the effect is terminated.
# # [28]
Transfer factor At the sametime No effect in immune
enhancement or antibody
response
ND ↔ [115]
Indomethacin Daily s. c.
for 7 days
Decrease of the
cyclooxygenase activity
by 80 to 90 % in spleen.
Reduction of PGE2
# ND [113]
Poly A:U 2 h before and 2, 4,
and 6 days after
Activation of NK cell
activity
↔ ND [116]
Poly A:U At the sametime Polyadenylic
acid-polyuridylic acid (poly A: U)
is a non-toxic adjuvant that
potentiates both humoral and
cell-mediated immune responses
# # [27,117]
Cyclosporine Daily for 4 weeks It induces low inflammatory
response in spleen and liver.
No significant changes in spleen
macrophage population
ND " [107]
Corticosteroids 24 h before It has a broad
anti-inflammatory effects
" " [3]
Anti-Ia 24 h before It depletes mostly B cells
and some T cell subpopulation with
“suppressor” activity
ND ↔ [111]
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Table 2 Effect on bacterial counts in mouse spleen (CFU) after passive transfer of antibodies, cells or cytokines at
different phases of smooth virulent Brucella infection (Continued)
Anti-CD8+ T
cells
5 days before
and 3 per week
Depletion of CD8+ cells.
DTH response was unaffected
after treatment. Treatment abolished
the IgG antibody response without
affecting bacterial numbers.
ND " [111]
Anti-CD8+ T
cells
1 day before and
every 4 days after
Depletion of CD8+ cells,
significant increase of
Møs in spleen. No
significant effect in the
number of CD4+, NK or
γδ T cells
ND " [118]
Anti-CD8+ 1 day before and
every 3 days after
Depletion of CD8+
lymphocytes involved in
cell mediated cytotoxicity
of infected cells
ND ↔ [119]
Anti-CD8+ 2 days before and
1,4,7 10 days after
Depletion of CD8+
lymphocytes involved in
cell mediated cytotoxicity
of infected cells
ND " [56]
Anti-CD4+ 2 days before and
1,4,7 10 days after
Influences the Th1 profile
mainly INF-γ. It induces
basal levels of IL2 and IL4
ND # [56]
Anti-CD4+ Reduces granulomatous
inflammation, which
seems to be mediated
mainly by CD4+ T cells
ND ↔ [119]
Anti-CD25+ T
cells
3 days before Depletion of CD4+
regulatory T cells.
Increase levels of INF-γ
in spleen cells
ND # [120]
Anti-NK1.1cells 24 h before Depletion of NK cells and activity ↔ ND [116]
Anti-asialo-GM1 24 h before
and 3 day after
Depletion of NK cells and activity ↔ ND [116]
Anti-PMN-RB6 24 h before and3,
6, 9 days after
It depletes neutrophils
and a small population of
Møs. It does not affect the
course of brucellosis. In
some cases CFU decrease
in numbers after 9 days of
treatment
↔/# ND [48,
unpublished
results]
Anti-IL-10 1 day before and
4 days after
The levels of INF-γ
increase during the first
week of infection
# ND [121]
Anti-IL-10 1 day before and
4 days after
Augments the production
of INF-γ in spleen cells of
both, sensitive and
resistant mouse strains
# ND [122]
Anti-IL-12 4 h before, or 2 days after,
or 7 days after
Decrease in spleen weight
and spleen inflammation
in relation to infected
non-treated mice.
There is granuloma reduction and
low levels of INF-γ
" " [123,124]
Anti-IL-4 24 h before and
4 days after
Removal of IL-4 It depresses the Th2 Ab response and
indirectly may favor the Th1 response
# ND [122]
Anti-INF-γ 1 day before
infection
Reduces splenomegaly " ND [112]
Anti-INF-γ 1 day before and
every 5 days after
No significant effect was observed
even after administration with IL-12
ND ↔ [114]
Anti-INF-γ 1 day before and
4 days after
It removes secreted INF-γ and
depressed Th1 response
" ND [121]
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Table 2 Effect on bacterial counts in mouse spleen (CFU) after passive transfer of antibodies, cells or cytokines at
different phases of smooth virulent Brucella infection (Continued)
Anti-INF-γ 24 h before and
4 days after
It removes secreted INF-γ and
depressed Th1 response
" ND [122]
Anti-TNF-α 1 day before and
every 4 days after
No significant effect in the number
of PMNs, CD4, CD8, NK, γδ T cells or Møs is observed
ND " [118]
Anti-TNF-α 4 h before, or
2 days after, or 7 days after
Decrease in spleen weight and
spleen inflammation with respect to
the infected non-treated mice. INF-γ
is detected at normal levels
" ↔ [60,63,124]
Anti-TCRγδ The same day and
3 days after
Removes Tγδ cells if innate immunity.
Depletion has similar effect in
IL/17Rα KO, INF-γ KO and GM-CSF KO mice
" ND [60]
a (") Significantly higher numbers of CFU in spleen than in controls; (#) significantly lower numbers of CFU in spleen than in controls; (↔) No significant number of
CFU in spleen in relation to the controls; ND, not done.
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a slightly higher susceptibility in TLR4 knockout mice,
others have found that the absence of TLR4 does not in-
fluence Brucella replication (Table 1). Brucella LPS sig-
nals through TLR4 but very inefficiently [50,125] and the
reported susceptibility associated with TLR4 is not as
large as that observed for other Gram-negatives [48].
Mutations in the iNOS and gp91phox, which affect several
innate immunity pathways, are not lethal and favor the
replication of Brucella, mainly at later times (Table 1).
Hybrids harboring double mutations in some of these
genes (e.g. iNOS/ICSBP) display profound deficiencies
that favor Brucella replication (Table 1).
Defects in the adaptive immune response generate di-
vergent phenotypes (Table 1). For instance, mutations
such as rag1, which hampers the maturation of some
populations of B and T cells, do not have significant in-
fluence in Brucella replication. In the case of the igh6
mutation that impedes the development of B lympho-
cytes, there are contradictory reports: while some
authors detect a decrease of Brucella CFU in the spleens
of igh6 mutant mice after the 1st week [55], others do
not notice significant changes at early times, and barely
some decrease at later times [54]. On the contrary, dis-
ruption of β2m or perforin (pfp) genes (that impact on
the development and function of cytotoxic CD8+ T cells)
seems to favor Brucella replication. However, there are
reports indicating that the β2m mutation either does not
have any influence [55] or supports the elimination of
Brucella later in the infection [54]. Nonetheless, rag1
and igh6 knockouts have problems in eliminating extra-
cellular non-virulent Brucella VirB mutants [126], sug-
gesting that these genes may play some role [54].
Knockout mice showing other immune defects do not
yield clear-cut results (Table 1). For example, mice with
defects in IRF-2 (a transcriptional factor regulated by
INF-γ), Cd4 (with a defect in the CD4+ T subset), or Aβ
(MHC-II deficient) seem to eliminate Brucella more effi-
ciently than the parental strains. However, some authors
do not report changes in spleen CFU in Aβ deficientmice [55]. IRF-2 knockout mice also have a conspicuous
defect in NK cells, but these cells do not play a relevant
role against Brucella infection [53]. The absence of CD4
+/CD25+ regulatory T cells (involved in the down regu-
lation of T cells) in Cd4 and Aβ mutant mice may bal-
ance the response towards Th1, thus favoring the
elimination of Brucella [54].
From experiments in mutant and knockout mice a few
general conclusions may be drawn. For instance, several
factors of the innate immune system that in other bac-
terial infections play an essential role, seem to be of
minor importance (e.g. iNOS, type-1 INFr, and gp91phox)
or irrelevant (e.g. IL-1β, IL-18, TLR4, TLR5, TLR2,
NOD1, NOD2, GM-CSF, IL/17r, Rip2, TRIF, NK or
Nramp1s) in murine brucellosis. It is also clear that Th1
response via INF-γ is crucial for controlling Brucella rep-
lication and that any event that negatively influence the
generation of this cytokine (e.g. ifng, IRF-1, IL-12KO) se-
verely compromise the overall adaptive immune re-
sponse against brucellosis. Finally, the absence of some
cell populations of the immune system (e.g. igh6, IRF-2,
Cd4 and Aβ) seems to favor the elimination of Brucella,
a fact that suggests that some regulatory phenomena are
induced during infection. All these events are in agree-
ment with the evolutionary stealthy strategy that Bru-
cella has followed to hide from and modulate the
immune system [4,48,125].
Age and sex
In the only study published on the influence of age [30],
it was reported that a B. abortus 2308 dose of
4 × 108 CFU/mouse was similarly non-lethal for 2 and
18 month old DBA/2 mice, and that a ten-fold higher
dose killed all animals in both age groups. Although such
clear-cut differences between these two very high doses
of a virulent strain are striking (see Infective Dose,
above), these results may indicate that age does not sig-
nificantly influences the susceptibility to lethality by B.
abortus. However, whereas the bacterial counts in the
spleen remained relatively high and stable for at least
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in the spleen of older mice after the 5th week. In the
same work, it was reported that the anti-Brucella im-
mune responses in older mice were less-Th1 specific and
showed higher levels of IL-17, and the authors suggested
alternative pathways for combating brucellosis in aged
mice.
With the exception of the Brucella "resistance" charac-
ter of C57BL mice, which seem to be partially dominant
with polygenic control in females [41,42], no compara-
tive studies have been performed between sexes. The pla-
centa becomes infected in pregnant female mice and the
testes constitute a site of Brucella colonization in the
case of males [74,76,127,128], two facts that are reminis-
cent of the events in domestic ungulates and humans
with brucellosis [129,130].
Transmission
Brucella horizontal and vertical transmissions are com-
mon in natural hosts [131] but rare in mice and humans
[132,133]. Although the mammary glands of nursing
dams are colonized with Brucella, less than one percent
of the mouse pups become infected [132,133]. Similarly,
Brucella colonizes salivary glands, kidneys and testes, but
venereal transmission or contagion rarely occurs [25,76].
This is striking since rats (closely related to mice) shed
the bacteria in the urine and they are prone to transmit
Brucella by the venereal route [134].
Transmission of virulent B. abortus 544 from the
mother to the fetus was demonstrated in mice [25,133],
with profuse infection of placentas [127]. Although mice
seem to be quite resistant to abortion, this event can be
induced at specific time periods. Attenuated B. abortus
S19 is also transmitted to the fetus, but it seldom
induces abortion [135]. These two events are somewhat
reminiscent of what happens in the natural host [136].
Physiopathology
The inoculation of virulent brucellae induces clinical and
physiopathological responses in mice that differ from
those caused by attenuated or non-virulent Brucella
strains [53]. These responses are less severe in Brucella
vaccinated or immunostimulated mice and more con-
spicuous in pregnant or immunodeficient mice (Table 1).
In the following paragraphs, the main events taking
place during different infection phases are described
(Figure 1A).
Onset of the infection
Optimal doses (e.g. 104 to 5 × 106 CFU/mouse) of viru-
lent brucellae by the i.p. or i.v. routes barely induce phy-
siopathological symptoms at early stages of infection.
The absence of obvious clinical signs correlates with: i)
normal blood cell and platelet counts; ii) the lack of arecruitment of proinflammatory cells at the site of infec-
tion; iii) the presence of minimal levels of serum IL-1β,
TNF-α, IL-10 and IL-6; iv) very low amounts of MCP-1
and RANTES chemokines [48,137]; and, v) the absence
of synthesis and degradation of fibrinogen and coagulo-
pathies [48]. IL-10 is not detected in serum and its corre-
sponding transcript only appears after 3 days of infection
[126]. Although IL-10 may be extracted from murine
spleen cells after 1 day of infection [138], the levels of
this cytokine are far lower than those induced by other
bacteria [139,140]. This suggests that the regulatory role
of IL-10 is minor or irrelevant at early times of Brucella
infection. At these early times, INF-γ and IL-12, are
barely detected in serum or cell extracts and these cyto-
kines become evident only during the next infection
phase [63,135,137,138,141]. However, the low levels of
INF-γ and IL-12 are not unique to early Brucella infec-
tions, since they are also observed at the onset of murine
salmonellosis [142]. Although transcripts of CXCL1 and
MIP-2 chemokines, and IL-6 can be detected in spleen
cells one day after infection [65], their levels are signifi-
cantly lower than those induced by other bacteria. Anti-
Brucella antibodies and IL-4 are not detected in serum
or in spleen cells at the onset of the infection [138,143].
In summary, the proinflammatory response to virulent
brucellae is very low and it may have some significance
only when compared with that induced by non-virulent
strains such as VirB or BvrS [37,126].
A few hours after infection, Brucella is detected inside
phagocytic cells in the blood, spleen, liver and bone mar-
row of mice [14,15,76]. In the liver, bacteria are detected
in sinusoids and within Kupffer´s cells as early as 3 h
after i.p. inoculation. During the first 6 h, neutrophils
gather around macrophage Kupffer´s cells; thereafter, the
number of bacteria decreases and seems to disappear
due to engulfment by liver phagocytic resident cells,
which become engorged with intracellular brucellae
[14,15]. During the early phase of infection, spleen
macrophage, neutrophil and colony forming cell num-
bers are not significantly different from those of non-
infected mice [28,43].
At the onset of infection, a normal distribution of
spleen cells is observed with some minor congestion and
presence of T cells, preferentially located in the periarter-
iolar lymphatic sheaths and within the red pulp. Con-
comitantly, B lymphocytes are mostly present in the
corresponding B-cell zones, marginal zones and red pulp,
while granulocytes and macrophages are scattered in the
red pulp and marginal zones. Activated phagocytes
expressing iNOS are not observed at these early times of
infection [65]. Treatment of mice with the immune en-
hancer poly A:U 1 h before infection does not affect the
number of CFU/spleen during the first 24 h. Neverthe-
less, it promotes the elimination of the bacteria after
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innate immune system is detrimental for Brucella multi-
plication and that, when professional phagocytes are
properly activated in vitro or in vivo, they are capable of
eliminating the invading Brucella [48,117].
Acute phase
This phase (from the 3rd day to the 2nd-3rd week) is
marked by the rapid increase of bacterial numbers in the
target organs, a significant inflammation of the spleen
and lymph nodes and the appearance of the first patho-
logical lesions in the liver. In addition, there is a develop-
ment of type IV delayed type hypersensitivity (DTH),
corresponding with the beginning of the Th1 response
[65,144]. Brucella can be readily isolated from blood and
many organs. However, as time passes by, it becomes
more difficult to find the bacteria in blood. Organ cell in-
filtration becomes significant at the end of this phase, with
augmented frequencies of phagocytic cells [14,15,43,65].
During the acute phase the non-gravid uterus, lungs, heart,
kidneys, brain and gastrointestinal tract do not show
conspicuous pathological signs [145].
The liver is the first organ to show significant histo-
pathological changes. Mild perivascular mononuclear
infiltrates are observed after the 3rd or 4th day of infec-
tion with virulent Brucella, because of the localization of
bacteria inside Kupffer´s cells. Thereafter, granulomas
become conspicuous, reaching their maximum intensity
after the 1st week of infection (Figure 3). Granulomas areFigure 3 Liver pathology and intracellular detection of Brucella antige
with virulent B. abortus 2308. (A) Liver granulomas (pointed by white arr
cells (black arrow and insert). (C) Mononuclear infiltrate formed mainly by m
detection of Brucella LPS antigen in matching histological sections of the c
and hematoxylin counterstain (D-F).composed by clusters of macrophages and dendritic cells
[146], generally known as epithelioid cells and histio-
cytes, several of which demonstrate ingested material as
well as Brucella antigens (Figure 3). The presence of
plasma cells and lymphocytes becomes evident, but very
little or negligible granulocyte infiltration is present in
the liver in this phase. At this stage, liver pathologies
induced by the virulent B. abortus 2308 and the attenu-
ated S19 strain are not significantly different. Mice
infected with non-virulent Brucella BvrS/BvrR or VirB
mutants do not generate significant pathological
responses in the liver or the spleen at any stage of the in-
fection [126, and Grilló, Blasco and Moreno, unpub-
lished results]. However, some immunodeficient mice,
like the IRF-1 mutants, develop more and larger liver
granulomas during the acute phase when infected with
virulent or attenuated B. abortus [53].
During the 1st week of infection with virulent Brucella,
the spleen sizes increases (Figure 2A), showing a mild
lymphoid depletion in the splenic nodules, moderate
macrophage infiltration, few neutrophils and a mild
extramedullary hematopoiesis in the red pulp [64]. In
spite of this, the overall number of macrophages and
neutrophils remains practically unaltered [43]. As expected,
higher doses of smooth brucellae (e. g. > 107 CFU/mouse)
induce larger inflammation [19,145]. During the 1st week of
the acute phase, the numbers of macrophages, neutrophils,
CD4+, and CD8+ T cells remain grossly within the limits of
uninfected spleens (Figure 4) [57,65,118]. After 10 days ofns in macrophages of BALB/c mouse after 10 days of infection
ows). (B) Large and smaller liver granulomas (white arrows) with giant
acrophages and histiocytes (white arrow). (D-E) immunoperoxidase
orresponding upper A, B and C panels. Hematoxylin-eosin stain (A-C)
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augment and the degree of lymphocyte depletion, macro-
phage infiltration and extramedullary hematopoiesis dis-
playing mitotic cells is prominent. Some macrophages may
have intracellular Brucella antigens.
At the end of the acute phase, the number of macro-
phages and neutrophils in the spleen increases slightly
(Figure 4A) [43]. While the B-cell areas remain popu-
lated and the CD4+ and CD8+ T lymphocytes have
decreased in the splenic nodules, the T-cell zones have
been displaced by macrophages [112]. The overall numberFigure 4 Spleen cell population profiles and histopathology
after infection of BALB/c mice with B. abortus 2308. (A) Spleen
cell populations. The total number of CD4 T cells, CD8 T cells,
neutrophils (PMN) and macrophages (Mø) per spleen was
determined by multiplying the percentage of positive cells obtained
by differential microscopy observation after cytospin centrifugation
and fluorescent flow cytometry analysis by the total leukocyte count.
Standard deviation at all points is lower than 10 % of the respective
value (adapted from [57]). (B) Spleen histopathology and detection
of Brucella antigens in the spleen. (a) Normal spleen (arrow points to
the central artery). (b-f) Histological sections of spleen nodules
during the acute phase of infection with virulent B. abortus 2308 (b)
Spleen nodule with a clearer area infiltrated by macrophages (arrow
points to the central artery). (c) Macrophage and histiocytes (arrow)
infiltrating the spleen nodule. (d) Active extramedullary
hematopoiesis (white arrow and insert) with granulomas (black
arrow) in some areas of the spleen. (e) Immunoperoxidase detection
of Brucella LPS antigen around the central artery of a spleen nodule.
(f) Immunoperoxidase detection of Brucella LPS antigen within
macrophages (arrow).of B cells and CD4+ and CD8+ Tcells in the spleen is slightly
higher than in spleens of uninfected mice [57,64,112,118].
Nevertheless, the confined depletion of lymphocytes seems
to be relative to the spleen swelling, rather than to a true de-
crease in cell content [147].
During the acute phase there are just a few but signifi-
cant differences between the spleen cell profiles induced
by the virulent B. abortus 2308 in comparison to that
generated by the attenuated vaccine S19. One week after
inoculation, S19 produces a relatively more severe local
lymphoid depletion than strain 2308 [64]. This corre-
sponds to a slightly larger spleen size in S19 infected
mice (Figure 2A), which also displays more intense neu-
trophil infiltration [64]. However, the most significant
differences in the pathological signs induced by virulent
and attenuated vaccine strains are evidenced at the end
of the acute phase and in the next phase. Non-virulent
brucellae (e.g. BvrR/BvrS) fail to induce significant spleen
changes and hardly any signs of inflammation.
After the 1st week of the acute phase, significant amounts
of INF-γ, IL-12, IL-6 and RANTES are present in sera of sus-
ceptible mice (Figure 5) [114,135,137,141,148,149]. After the
2nd week, these cytokines steadily decrease approaching basal
levels by the 6th week, already in the next infection phase
(Figure 5A). The endogenous IL-12 extracted from spleen
cells of infected mice seems to parallel the kinetics in sera, al-
though at lower levels [138,148]. Similarly, endogenous INF-
γ (and its transcript) attains maximum levels during the first
2 weeks of the acute phase and is still detected (albeit at sig-
nificant lower levels) after 8 weeks, in contrast to endogenous
IL-12 [65,138]. The difference between serum and endogen-
ous INF-γ suggests that it may still remain as a reservoir pool
inside cells of susceptible mice, but not released into circula-
tion at later times. In contrast to what happens in the suscep-
tible BALB/c mice, the resistant C57BL/10 strain does not
display INF-γ in serum during the acute phase [114]. More-
over, the INF-γ kinetics profile depends on the Brucella viru-
lence. For example, INF-γ levels decrease faster after
inoculation with attenuated S19 than after infection with
virulent B. abortus [65,141].
Cultured spleen cells from infected mice are able to
generate cytokines after ex vivo challenge with Brucella
antigens. In this ex vivo protocol the kinetics of IFN-γ
parallels those of GM-CSF and IL-10 production, dis-
playing an early rise by the 3rd or 4th day after infection,
reaching peak levels between days six and ten, and then
declining sharply [65,150,151]. Regardless of whether the
assays are performed in sensitive or resistant mouse
strains, both IL-12 and IFN-γ are produced ex vivo dur-
ing secondary stimulation of cultured spleen and CD4+
T cells with Brucella antigens during the 1st week of in-
fection [92,114,122]. However, by the 3rd week of infec-
tion, at the beginning of the next phase, there is a
decrease in IL-12 receptor-2 expression in spleen cells of
Figure 5 Cytokine and antibody serum profiles of B. abortus
2308 infected mice. (A) Serum cytokine levels in BALB/c mice after
infection with virulent B. abortus (INF-γ, TNF-α, RANTES) or
attenuated vaccine S19 (IL-6, IL-12) stains (adapted from
[135,137,148,149]). (B) Antibody response of virulent B. abortus 2308
infected CD-1 mice (adapted from [138]). Notice that in “A” the
absolute units are different for each cytokine, according to the
indication (e.g. while TNF-α, INF-γ, RANTES are measured in pg/mL,
IL-12 are in pg/mL/5 and IL-6, in Units/mL). For clarity, the SD were
not included.
Figure 6 DTH in B. abortus S19 infected mice after footpad
injection of Brucella protein extracts. Note the biphasic response
between the acute and chronic steady phases. The blue line in the
graphic is compatible with type IV hypersensitivity, while the red line
is compatible with a mix reaction of type IV and type III
hypersensitivity (adapted from [153], with permission).
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ability to produce IFN-γ at later times [114,122]. In this
mouse strain the IFN-γ levels remain low until the end
of the next phase, close to week 10 pi. Then, the spleen
cells can be specifically restimulated with Brucella anti-
gens to generate this cytokine [65].
During the acute phase, the production of IL-18
(which works synergistically with IL-12 to induce the
generation of INF-γ) is depressed in spleen cells of B.
abortus infected mice [144]. Therefore, once the infec-
tion has been established, the limited secretion of IL-18
does not affect the endogenous production of IFN-γ.
Simultaneously, small amounts of endogenous IL-10
(and its transcript) reach their maximum during the 1stweek of the acute phase, disappearing from the spleno-
cytes during the 2nd week pi [138]. It may be that the en-
dogenous synthesis of IL-10 could, after all, influence the
production of IFN-γ and the premature development of
the Th1 response.
Although anti-Brucella antibody producing cells are
present in the spleen early after infection, relevant levels
of anti-Brucella immunoglobulins are detected only after
the 2nd week pi (Figure 5B), with relatively higher levels of
IgG3 [30,65,67,138]. DTH to Brucella antigens becomes
evident during the acute phase [153], reaching its
maximum at 9 days pi (Figure 6). The second event
(Figure 6, red line) observed after the 2nd week may cor-
respond to a mixture of type III and IV hypersensitivity
reactions. However, macrophages display their maximum
unspecific killing activity at 18 days pi, at the end of the
acute phase and persist for 4 weeks, albeit, at lower levels.
This phenomenon is known as the Mackaness effect [153],
described as “an immune response specifically induced but
non-specifically expressed”. In addition, cultured spleen
cells from Brucella infected mice do not proliferate in re-
sponse to challenge with killed Brucella or soluble anti-
gens (Figure 7) [152]. This suggests the presence of
regulatory phenomena at this stage [4]. Only negligible
amounts of TNF-α (Figure 5A), IL-4 and MCP-1 are
present in the sera of Brucella infected mice in the acute
phase and thereafter [38,63,135,137,138]. IL-2 and IL-4 are
barely detected in spleen cells from infected mice stimu-
lated with Brucella antigens during the acute phase
[92,122,151]. The quality of Brucella antigens profoundly
Figure 7 Spleen cell proliferation (3 H-thymidine incorporation)
in response to killed B. abortus 2308 in BALB/c mice infected
with B. abortus virulent 2308 or vaccine-attenuated S19 strains,
during 20 weeks [adapted from [152] with permission]. Notice
the delay in response of spleen cells from 2308 infected mice in
relation to those infected with the attenuated strain S19.
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spleen cells from mice infected with live Brucella display a
Th1 response marked by INF-γ and IL-12 production.
However, spleen cells from mice immunized with soluble
Brucella antigens generate preferentially a Th2-like re-
sponse, with IL-4 and IL-2 production by CD4+ T cells
[151]. In addition, there is a higher frequency of precursor
IFN-γ-producing CD4+ T cells and a lower frequency of
precursor IL-4-producing CD4+ T cells in B. abortus
infected mice than in mice immunized with Brucella sol-
uble antigens [151].
Acute phase in pregnant mice
Pregnant mice offer a special environment for Brucella
replication [145]. Murine brucellosis during pregnancy
has been explored mainly throughout the acute phase,
because the mouse gestation time has an average of
19 days. B. abortus (i.p. 104 CFU/mouse) induces higher
“abortion” rate (death pups on day 18.5, before natural
delivery) when administrated on day 4.5 of pregnancy
than when injected at later times of the gestation
[135,137,154]. The degree of colonization and placental
damage depends on the doses and the pregnancy period.
After the 7th day of pregnancy, doses lower than
2 × 105 CFU/mouse seldom induce miscarriages or fetal
deaths, independently of the infection route. This is an
indication of the mouse resistance against Brucella-
induced abortion [74,127,132,133]. However, in close
parallelism to the events in natural hosts, placentas aremore intensively colonized when mice are challenged
during mid pregnancy (days 7–11) than when inoculated
during early (e.g. day 3) or late (e.g. day 15) pregnancy
[135,137,154]. Placental colonization and abortion are
not always linked. In some experiments, virulent B. abor-
tus 2308 colonizes the placenta without inducing abor-
tions, although it may cause fetal deaths [145]. When
mice are infected at day 9 of gestation, the invaded pla-
centas have lost weight, look edematous and frequently
harbor pale and shrunken autolyzed fetuses 9 days later
(day 18 of pregnancy) [145]. Strikingly, mice born alive
from infected dams do not demonstrate gross macro-
scopic or microscopic alterations [145], and no differ-
ences in bacterial loads between the live and aborted
fetus are detected [135]. All these observations suggest
the existence of refractory “placental windows” to Bru-
cella infection. Attenuated (e.g. S19) and non-virulent
Brucella (e.g. VirB mutants) seldom induce abortions, al-
though S19 may cause restricted placental infections
[38,137].
Brucella replicates within giant trophoblasts located in
the deciduas basalis, 3 days after infection of mice in the
12th day of pregnancy (Figure 8) [135]. Two days later,
most bacteria are already found within giant tropho-
blasts, and necrotic foci become evident within the spon-
giotrophoblastic zone. Inflammatory cells are mainly
found along the regressing layer of the endometrium
overlying the implanted chorionic vesicle, or free within
the newly formed uterine lumen [135]. The occurrence
of neutrophils is likely the result of tissue destruction in
necrotic areas. Indeed, when bacteria are solely located
within giant trophoblasts with no cell destruction, neu-
trophilic inflammatory response is not observed. This
confirms the absence of granulocyte recruitment by Bru-
cella organisms at the site of infection [48]. A multifocal
necrosis of the spongiotrophoblastic zone of the placenta
coalescing in several zones is produced, 7 to 9 days after
infection (corresponding to 16 to 18 days of gestation)
[135]. In this region, which extends from Reichert’s
membrane at the periphery of the disk to the interior,
extracellular bacterial colonies are present together with
a few giant trophoblasts remaining infected. Throughout
the necrotic regions, there is massive bacterial
colonization and phagocytosis of Brucella. In some
placentas, thrombosis of the uterine vessels in the
junctional zone resulted in infarction of the labyrinth
zone. All these lesions resemble those observed in the
placentas of Brucella infected natural hosts [89].
Abortion in mice seems linked to INF-γ increase,
RANTES production and to low expression of heme
oxygenase-1 in the giant trophoblasts [135,137,154].
Neutralization of INF-γ and RANTES inhibits abortion
in mice inoculated with Brucella at day 4.5 of gestation.
Moreover, down-regulation of heme oxygenase-1
Figure 8 Brucella invasion of mouse placenta. (A) Model of a mouse placenta with trophoblast giant cells (in ocher) infected with Brucella (in
red). (B) Immunochemical detection of intracellular Brucella inside giant trophoblasts (arrows) of ICR mice infected with virulent B. abortus 544, at
15 days of gestation; Meyer's hematoxylin stain. (C) Indicate the magnified image from panel (B) (adapted from [135], with permission).
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treatment. TNF-α or MCP-1 are not involved in Brucella
induced abortion in mice. Non-virulent Brucella VirB
mutants do not lower the amounts of heme oxygenase-1
in murine giant trophoblasts and barely induce produc-
tion of INF-γ, RANTES.
Chronic steady phase
The chronic steady phase (from the 3rd to the 8th–11th
week) is noticeable by high levels of infection, describing a
plateau with a maximum and sustained number of CFU in
the target organs (Figure 1A). During this phase, bacteremic
episodes are transient and the chances to isolate Brucella
form blood are scarce. The liver granulomas increase in
size, mainly because of the merging of disperse smaller
granulomas developed in the acute phase [59]. At this stage,macrophages contain Brucella antigens, indicating bacterial
destruction within phagocytes [59]. Some macrophages fuse
and become polykaryons and multinucleated giant cells
within the well demarcated liver granulomas. Commonly,
these giant cells are located in the granuloma centers and
contain from 5 to 20 nuclei (known as Langhans cells). The
bone marrow of infected mice also shows granulomas but
the lungs, heart, kidneys or gastrointestinal tract do not
show significant pathological lesions [88,145]. The appear-
ance of granulomas and giant cells in the liver seems to cor-
respond to an innate phenomenon not mediated by T cells.
Indeed, granulomas and giant cells equally occur in normal
and athymic nude mice [59]. The number and size of
liver granulomas are larger in mice infected with
virulent B. abortus than with attenuated S19. More-
over, mice infected with S19 seldom display giant
Figure 9 Spleen inflammation after infection of BALB/c mice
with attenuated B. abortus S19 vaccine strain or virulent B.
abortus 2308 (A) Generation of granulomas in the spleen
(adapted from [64], with permission). (B) Histological sections
stained with hematoxylin-eosine of spleens of CD-1 mice infected
with B. abortus S19 after 6 weeks and with B. abortus 2308 after
8 weeks. As shown in Figure 2a, the spleen of S19 inoculated mice
after 6 weeks of infection is considerably smaller than those infected
with 2308. The proportion of the white pulp has been reestablished
and the number of macrophages and neutrophils in the periphery of
the central arteries of the nodules has considerably diminished in
the spleens of S19 infected mice in relation to those infected with
virulent 2308 strain, which is hyperemic and infiltrated with
inflammatory cells.
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with non-virulent Brucella do not enter into this
phase; therefore, granulomas are rarely present.
After the 2nd week of infection and parallel to spleen
swelling (Figure 2B), granulomas and giant cells increase in
this organ, until the middle of the chronic steady phase (5th
to 6th week) (Figure 4B). Thereafter, there is a slow decrease
in the size and number of granulomas. This becomes
evident at the end of the chronic steady phase (Figure 9)
[64]. During the 3rd week pi, the apparent depletion of lym-
phocytes in the white pulp reaches its maximum. Then,
after the 4th week, there is a gradual increase in lymphoid
hyperplasia and extramedullary hematopoiesis with several
mitotic figures and multifocal accumulation of macrophages
that surround and sometimes cover the periarteriolar
lymphoid sheaths (Figure 4B). In spite of the apparent
lymphocyte local depletion, the total number of CD4+ and
CD8+ cells increases moderately (two and one fold, respect-
ively) about the 3rd week of infection (Figure 4A) [57,118].
Along with this, infiltrating macrophages and neutrophils
increase to relatively large proportions (seven and eight fold,
respectively) (Figure 4). This increase is proportional to the
swelling and infiltration of blood and phagocytic cells in the
spleen. However, there is some controversy regarding the
suggested lymphocyte depletion in the spleen of infected
mice [65]. Morphometric and histopathologic analysis of
spleens of B. abortus infected mice do not reveal significant
decrease in lymphocytes in the white pulp [147]. This indi-
cates that the apparent depletion of lymphocytes is a local
phenomenon related to the inflammation and influx of
blood, rather than an absolute decrease of these cells.
At the end of the steady chronic phase, the splenomeg-
aly has already decreased (Figure 1A) and splenocytes
come close to normal numbers and distribution [57,64].
Parallel to the reduction of macrophage infiltration and
B cells repopulation of the germinal centers, the CD4+
and CD8+ T lymphocytes recolonize the periarteriolar
lymphatic regions [65]. By this time, colocalizing Bru-
cella antigen and iNOS-positive activated macrophages
are observed in periarteriolar lymphatic sheaths [65]. At
these later times, Brucella antigens confined in macro-
phages are still present in the spleen [152]. However,
there is no significant change in MHC-I or MHC-II ex-
pression on the surface of spleen macrophages [118].
After the 4th week, the differences between spleens of
mice infected with virulent or attenuated B. abortus S19
become evident [2]. The number of spleen granulomas
in mice infected with virulent B. abortus is signifi-
cantly higher (Figure 9), displaying extensive hyper-
plasia of the periarteriolar tissue. In addition,
extramedullary hematopoiesis, neutrophil and macro-
phage infiltration are significantly higher in mice
infected with virulent Brucella. Following the decline
of S19, a decrease in splenic granulomas, neutrophilinfiltration and extramedullary hematopoiesis is observed.
However, the number of macrophages remains high
and lymphoid hyperplasia is evident (Figure 9). The
emergence of large germinal centers in the spleen
with reduction of macrophage accumulations does not
occur before 6 to 10 weeks pi with S19, and after
10 weeks pi with the virulent strains. The presence of
antigen in macrophages persists longer in mice
infected with virulent B. abortus than in those inocu-
lated with S19 [152].
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proliferate at 6 weeks pi while the splenocytes of mice
inoculated with virulent B. abortus multiply later (Figure 7)
[17,152]. This phenomenon (linked to the virulence of Bru-
cella strains and to the severity of the infection) is consist-
ent with the observed pathological changes of the spleen
and suggests some inhibitory action related to the presence
of regulatory CD4+CD25+ T cells [4,120]. This is also in
agreement with the tendency of spleen lymphocytes from
mice repeatedly immunized with Brucella antigens to pro-
duce less INF-γ when stimulated in culture with the cog-
nate antigen [155]. It is worth noting that cultures of spleen
cells proliferate in response to Brucella antigens 2 weeks
earlier when mice are infected with the attenuated rough B.
abortus RB51 than when infected with S19 [152]. This event
seems to be related to the lesser spleen inflammation and
faster elimination of the rough strain in relation to smooth
bacteria. It seems, therefore, that in murine brucellosis the
immune regulatory events are linked to the overall bacterial
virulence, rather than to specific bacterial mutations.
infected BALB/c mice produce substantial amounts
of serum IFN-γ during the acute phase but much less
during the chronic steady phase (Figure 5A). On the
contrary, in the resistant C57BL/10 serum IFN-γ is
just detected in significant amounts at latter phases
(50–75 days), corresponding to bacterial clearance in
this strain of mice [114]. The lack of measurable IFN-γ
in the serum of infected mice does not necessarily
mean that cells are not producing this cytokine in re-
sponse to Brucella infection (in order to detect IFN-γ
in serum, relatively large amounts of this cytokine
need to be produced) [114]. Nevertheless, in clear con-
trast to the C57BL resistant mouse strain, the levels of
IFN-γ produced ex vivo by BALB/c spleen cells are
about two fold higher during the 1st week of the acute
phase. Then, a hiatus in IFN-γ production is observed
in the sensitive but not in the resistant mice at the be-
ginning of the chronic steady phase [118]. In the mid-
dle of the chronic steady phase, the amount of IFN-γ
secreted by stimulated splenocytes of BALB/c is rees-
tablished and parallels those of the resistant mice
[118]. This difference does not relate to a lower ability
of BALB/c to generate IFN-γ because in vitro stimula-
tion of naïve splenocytes later in time generates com-
parable quantities of this cytokine in both murine
strains [118]. Rather, it seems connected to a reduced
expression of the IL-12 receptor in BALB/c mice.
Since responsiveness to IL-12 is linked to INF-γ pro-
duction, a temporal suspension of the Th1 response
seems to occur in BALB/c at the beginning of the
chronic steady phase [114,118]. It is important to note
that IFN-γ production appears to be mainly promoted
by CD4+ rather than by CD8+ lymphocytes [65,149].Serum IL-6 peaks at the end of the acute phase and
remains relatively high until the first 2 weeks of the
chronic steady phase [149]. Moreover, upon stimulation
with killed Brucella, spleen cells from infected mice still
produce significant amounts of IL-6 in the middle of the
chronic steady phase [149]. Similarly to the production
of IFN-γ, the generation of IL-6 seems to be mainly pro-
moted by CD4+ lymphocytes [17,65,149]. However,
while the ex vivo generation of INF-γ only responds
to the cognate antigen, the ex vivo generation of IL-
6 can also be induced by heterologous antigens such
as killed Listeria [149]. This is reminiscent of the
Mackaness effect, in which the maximum activity
against live Listeria is expressed by the Brucella
infected mice at the beginning of the chronic steady
state, mainly through activated macrophages directly
stimulated by CD4+ cells [119,153]. IL-10, GM-CSF,
and IL-4 are barely secreted during most of the
chronic steady phase by spleen cells of Brucella
infected mice challenged ex vivo with cognate anti-
gens [17,65,122,138]. In addition, CD4+ cells stimu-
lated ex vivo with Brucella antigens produce close to
twenty times less IL-2 than the same cells stimulated
with concanavalin A [17]. At the end of this phase,
splenocytes may be re-stimulated to produce INF-γ,
IL-10, GM-CSF and IL-2 [65]. The significance of
this is unclear. Increase of spleen regulatory T cells
may be directly involved in the suppression of ef-
fector T lymphocytes devoted to cytokine release and
to the control of the infection [4,120].
Th1 immunity is also denoted by the distribution
of different antibody isotypes against Brucella LPS
during the chronic steady phase (Figure 5B). While
no endogenous production of IL-4 is detected at any
time during infection, there is a predominance of
IgG3 and IgG2a, with a minimum response of IgG1
at the end of the acute phase and up to the 14th
week pi [138]. In addition to the anti-LPS specific
response, a polyclonal IgG3 and IgG2a production
dependent upon the endogenous IFN-γ has also been
observed in B. abortus infected mice [143] as well as
in mice immunized with killed Brucella [156]. More-
over, the IgG3, IgG2a, IgG2b, IgG1 isotype profiles
generated against purified Brucella LPS are also gen-
erated in both euthymic and athymic mice [157].
This suggests that INF-γ influences the IgG isotope
synthesis in mice by Th1-dependent mechanisms and
also by T-independent responses.
One striking phenomenon is the second wave in the
increase of foot-pad thickness observed between the 3rd
and 8th week (Figure 6). Although this second wave has
been related to type IV delayed hypersensitivity reaction
[153], it corresponds most likely to a mixed reaction with
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creasing levels of antibodies and antigen after the 2nd
week of infection (Figure 5B) are in agreement with the
occurrence of a type III reaction.Figure 10 Antibiotic treatment and antibody response of B.
melitensis 16 M infected mice. Blue, pink and white circles
represent log10 CFU/spleen in the left ordinates axis of the figure.
White and black squares represent ELISA values at the right
ordinates axis of the figure. Notice that the antibody titers in mice
treated with antibiotics remain high over the 34 week period of the
assay, in spite of the disappearance of Brucella CFU from the spleen.
Some of the animals treated only with doxycycline may still harbor
bacteria after 34 week period (adapted from [158,159], with
permission).Chronic declining phase
Despite being longest (more than 250 days), the chronic
declining phase has been the least studied one [31].
Although there is a declining in DTH [119] and most
blood cytokines decrease or become undetectable, the
memory response seems fully consolidated because this
phase is characterized by a bacterial declining in the tar-
get organs and the progressive disappearance of spleno-
megaly and pathological lesions in liver and spleen [59].
The reduced number of liver granulomas [65] parallels
the decrease of IFN-γ. The spleen diminishes in size but
it seldom reaches a normal dimension, even at the latest
times of infection (Figure 2A), possibly because of the
persistence of small numbers of Brucella in several
organs, mainly in lymph nodes. Nevertheless, Brucella is
rarely isolated from the blood. Spleen cells maintain their
ability to be restimulated by Brucella antigens at least for
5 months after infection (Figure 6B) [152], demonstrat-
ing long lasting immunological memory against brucel-
losis [36]. Moreover, antigen stimulated spleen cells
produce GM-CSF, IFN-γ and some IL-10, but not IL-4, 6
to 12 months pi [65]. The secretion of INF-γ at these
later times is related to CD4+ T cells, since functional
blockade of CD4+ T cells by the addition of CD4+−spe-
cific antibody abrogates the cytokine response [65]. The
antibody levels stay high throughout the infection period
(Figure 10). The sequelae observed in chronic brucellosis
in humans and cetaceans [77,129] have not been
reported in mice.Vaccination
The availability of successful live Brucella vaccines for
over 75 years (since the discovery of S19) is outstanding
[6] because such early developments are exceptions
rather than a rule in the field of attenuated vaccines. In
spite of their success, the available anti-Brucella vaccines
are not perfect [22] and their use is restricted to bovines,
goats and sheep [16]. There is an increasing interest in
developing vaccines for humans and animals other than
those domestic ruminants, including wildlife, none of
which are covered by the available vaccines [87,128].
Routine testing of Brucella vaccines in the natural
hosts is precluded due to economical and practical diffi-
culties. Therefore, the mouse model has been extensively
used [16,22,33,36,68]. There is, however, substantial an-
archy in the protocols used. The literature is plenty of
experiments in which the protective efficacy is assessedby comparing the levels of infection of vaccinated and
non-vaccinated mice as the only control. By this criterion
alone, practically all live strains (no matter whether they are
partially or fully attenuated) or even killed Brucella provide
significant levels of protection [22,29,35,36,68,160]. More-
over, immunization with Brucella LPS, outer membrane
proteins, bacterial extracts or even with phylogenetically
related bacteria (e.g. Ochrobactrum) may reduce infection
with respect to unvaccinated mice [161-165]. The fact that
both cell mediated immunity and antibodies protect mice
against brucellosis [107,166] may explain in part why a
broad collection of immunogens have such a protective
action. A second factor to consider is the Mackaness effect:
an “unspecific” activation of the immune system that can
protect against Brucella challenge within certain periods
[153]. Other facts are the particularities of the immune
system and short life span of mice, as well as the experi-
mental time intervals used.
The protective efficacy greatly depends on the Brucella
virulence and challenge dose. Thus, a considerable number
of studies has been dedicated to standardize the mouse
model for vaccine testing [23,24,32,75,97,167,168]. As a
result, a standardized protocol for controlling the quality of
B. abortus S19 and B. melitensis Rev 1 vaccines has been
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(OIE) [16]. The premise of this model is the fact that these
efficient smooth vaccines retain a significant degree of per-
sistence in the host that renders them highly immunogenic
and protective [23,24,75]. Since a direct relationship
between attenuation and protective efficacy cannot be
unambiguously established, this model requires the simul-
taneous determination of two parameters [32-34,167,168].
The first parameter is the Residual Virulence expressed as
RT50 (see above). The second parameter is the Immuno-
genicity, defined with respect to the ability of the vaccinated
mice to control the number of bacteria in the spleen after a
standardized challenge [32] (see below). This pa-rameter
has to be analyzed at precise intervals after vaccination and
is expressed as the mean CFU number of the challenge
strain in the spleens. These two parameters do not stand
alone, and each vaccine candidate or new vaccine batch
should be compared with standard Rev1 or S19 reference
strains of known origin and performance. In the case of
Rev1 and S19, doses of 108 CFU/mouse injected by s.c.
route are used to define the RT50. The same statistical
approach may be applied to determine the RT50 of other
Brucella strains, no matter whether they are virulent, atte-
nuated or non-virulent. However, for non-virulent brucellae,
like the VirB or BvrS/BvrR mutants that persist just for a
short period, the intervals for spleen culture have to be
shortened (e.g. every 3 days) [37]. On the contrary, for
assessing the RT50 of virulent strains like B. melitensis H38,
B. melitensis 16 M, B. abortus 544, B. abortus 2308, and B.
suis 1330, the inoculum should be much lower (e.g.
104 CFU/mouse). This is so because the virulent Brucella
strains inoculated at larger doses (e.g. > 105/mouse) persist
longer than 30 weeks in the spleen and the RT50 calcula-
tion becomes unpractical [31]. The recommended mice are
outbred CD-1 or inbred BALB/c females, with body weights
ranging between 20–23 grams. Although these mouse
strains seem equally susceptible to Brucella, the optimal
challenge dose for immunogenicity assessment may vary
according to the age of the animals, whose body weights
relate to their particular growth rates (8–10 weeks of age
for BALB/c strain and 4–6 weeks for CD-1.
The original OIE protocol was expensive and cumber-
some. The graphical statistical procedures initially proposed
for determining the RT50 values had some mathematical
complexity and other unpractical inconveniencies that lim-
ited its use [33]. For a friendlier statistical tool that facilitates
the RT50 (details see Table 3). Two criteria must be met for
an adequate RT50 estimation: i) four time points must be
analyzed for presence of bacteria in the spleens; and ii)
these time points should be such that the first and the last
yield an accumulated percentage of cured mice≤ 16 % and≥
84 %, respectively. Statistical comparisons should be per-
formed exclusively between RT50 values obtained with the
same protocol and, ideally, in the same experiment.Alternatively, an indirect or relative estimation of the Re-
sidual Virulence of a given strain could be obtained asses-
sing the splenic growth curves described above. In this case,
at least one of the reference Rev1 or S19 strains has to be
included in the study [22].
For Immunogenicity assessment, mice are injected s.c.
with the reference vaccine at doses of 105 CFU/mouse.
Thirty days after vaccination, mice are challenged by the
i.p. route with the standard challenge dose (2 × 105 CFU)
of CO2-dependent B. abortus 544. Two weeks later, the
CFU of the challenge strain are counted in the spleens
using differential growth conditions for identifying
vaccine and challenge coloniesa. Under these conditions,
immunogenicity is expressed as the mean ± SD of log10
(X/log10X), where X is the number of CFU in each indi-
vidual spleen. The mean log10 (X/log10X) obtained in the
testing vaccine group should be compared with that
obtained in the vaccinated and unvaccinated control
groups, preferentially by ANOVA followed by the
Fisher's Protected Least Significant Differences tests.
Since protection against Brucella infection (at least in
the mouse model) is genus-specific and not species-spe-
cific [75,168], B. abortus 544 has been recommended as
the standard challenge strain, even when B. melitensis
Rev1 is used as vaccine. In spite of this, and whenever
possible, a homologous challenge strain should be used.
Accordingly, species-specific reference virulent strains
such as B. melitensis H38 or 16 M for anti-B. melitensis
vaccines, B. abortus 544 or 2308 for anti-B. abortus
vaccines and B. suis 1330 for anti-B. suis vaccines have
been used as a challenge in some works [22,72,75,81].
In all cases, the vaccine must also be easily distinguish-
able from the challenge strain. Live vaccines may survive
longer than the time of challenge, and even become reac-
tivated [23]. As consequence, they may be present when
the number of CFU of the challenge strain in the spleen
is estimated. To distinguish the vaccine and the chal-
lenge strains on the culture plates, markers like erythritol
sensitivity (e.g. S19), CO2 dependence (e.g. B. abortus
544), antibiotic resistance (e.g. B. melitensis Rev1) or
antibiotic sensitivity (e. g. B. abortus 2308 nalidixic acid
sensitive) have been used [22,75,87,171,172]. As an alter-
native, the vaccination-challenge interval can be
extended to ensure the complete elimination of the
vaccine from the spleen [23,24]. Following this method,
challenge with B. abortus 2308 or B. melitensis H38 in
BALB/c mice generally render more reproducible results
than those obtained with B. abortus 544 or B. melitensis
16 M [22,35,68,172]. One reason for this is that the two
former strains give a broader range of values between
controls inoculated with the placebo or the reference
vaccine. The replication of the challenge strain in mice
vaccinated with a reference vaccine (S19 or Rev1) is
lower than in unvaccinated mice during the first 2 weeks
Table 3 Problems when performing experiments with Brucella in the mouse model and general recommendations
Experimental
variables
Problems Recommendations
Mouse breed - Different susceptibility to Brucella infections.
- Heterogeneity of infection.
- Eight to ten weeks old (20 g) female BALB/c.- For BALB/c, n= 5
gives homogeneous spleen counts. For outbred breeds (e.g. CD1)
the number per group should be increased (n≥ 6) and the body
weight factor taken into account (see Vaccination). For the
recommended weight at the Mouse Phenome Database [169].
Target organ - Inconsistent infection in some organs. - Count CFU in spleens (consistently colonized in infected
animals; longer persistence than in liver or other organs) after
determining the individual organ weight.
Brucella wild-type
challenging strain and
virulence controls
- Attenuation by inappropriate storage and/or handling.
- Species, biovar and reference strain differences.
- Use only reference strains (B. abortus 2308 or 544, B. melitensis
16 M or H38, B. ovis PA, B. suis 1330). Aliquots should be
maintained in cryoprotective solution at–80°C (or below), or
freeze-dried at 4°C.- Stocks seeded on agar plates and then
cultured only once on new plates to obtain final inoculi.- Plates
checked for contaminants and freed from condensation or
syneresis water.- Make sure that reference strains reproduce
typical virulence patterns (see The Brucella strains: replication
patterns and related effects)
Attenuated Brucella
strains and virulence
control
- Over-attenuation by inappropriate storage and/or handling.
- Inappropriate infectious dose.
- Lack of appropriate controls.
- Competing events in superinfection protocols
- See above for storage and inoculum preparation.- Typical
multiplication (acute phase) and persistence (chronic phase)
patterns in spleens should be assessed.- Use adequate virulent
controls (see above, Wild-type strains). In genetic manipulation
experiments, consider appropriateness of complemented strains
and controls for unrelated attenuation cause by in vitro
manipulations.- Avoid using protocols in which mixtures of
virulent and attenuated Brucella strains are used as an attempt to
determine the relative virulence of the former in relation to the
latter bacteria.
Brucella
infectious dose and
route
- Not optimized for the purpose of the experiment.
- Dose not adequate to the route.
- Animal handling during inoculation.Intrinsic problems
in some routes.
- Use PBS pH 6.85 for preparing the inoculum.- In a preliminary
dose–response assay, determine the optimal dose/route (see
Route of the infection) for each Brucella species, biovar and
reference strain (e.g. B. abortus 2308 vs. 544 or B. melitensis 16 M
vs. H38) and also for each mouse breed. For outbred mice, doses
must also be adapted to the body weight/age (Physiopathology).-
The intraperitoneal route is recommended for most purposes. To
avoid intra-intestinal inoculation, displace the intestines and
inoculate in the lateral of the abdomen (not in the linea alba).
Intravenous inoculation in tail is exceedingly difficult and poses
repeatability problems, particularly in small breeds. Oral and
aerosol routes are not recommended (see Route of the infection).
Vaccination/attenuated
strains dose
- Inappropriate dose and route.
- Absence of controls
- For classical smooth vaccines, follow the OIE protocol
(1 × 105 CFU/subcutaneously).- To evaluate B. melitensis and B.
abortus vaccines, always include Rev1 or S19 reference strain
controls, respectively.
Time intervals
for virulence studies
Not meaningful. - For screening, analyze two times corresponding to the
multiplication phase and the persistence (e.g. 2 and 8 weeks post-
infection). For definite results, test four times (e.g. 2, 4, 6, and
8 weeks post-infection).
Assessment of
vaccine efficacy
- Challenge strain.
- Time intervals.
- Differentiation of vaccine and challenge strains.
- Use fully virulent reference strains and a control reference
vaccine strain (see above).- Challenge 4 weeks after vaccination
(see Vaccination).- Whenever possible, the challenge strain should
carry identifiable marker(s).
CFU determination - Limit of detection not optimized.
- Expression of results (CFU/organ vs. CFU/weight)
- Homogenize the organ in 1:9 (weight:volume) PBS and plate
100 μL by triplicate of each dilution (limit of detection of this
method= 3.3 CFU/mL of dilution, corresponding to less than
5 CFU/spleen)- Express the results as log CFU/organ and report
spleen weights separately (inflammation varies depending on the
Brucella strain and among mouse strains).
Evaluation of immune
response
- Presence of antigens and bacteria when
performing ex vivo experiments.
- Lack of correlation between transcripts
and protein immune mediators
- Lack of sensitivity- Lack of specificity
- Inappropriate plotting of data
- Procure APC from non-infected mice to avoid dragging antigen
or bacteria. Whenever possible perform direct assays (e.g. flow
cytometry, microscopy, cell protein extraction, and serum
detection).- Contrast the results obtained with indirect methods
with those generated by direct methods.- Use times of maximum
expression of cell types or immune mediators.- Consider the
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Table 3 Problems when performing experiments with Brucella in the mouse model and general recommendations
(Continued)
“Mackaness effect”.- Include a saturating control that could reveal
the real magnitude of the response. Whenever possible, avoid
expressing data in relative numbers or “fold responses” and
procure the inclusion of absolute values.
Assessment of
depletion of cells
and immune factors
- Inefficient depletion - Check antibody concentration, reactivity, dose and time intervals
of administration. Consider that depletion seldom last more than
8 days due to neutralization by generation of anti-antibodies
Statistical analysis - Inappropriate normalization
and statistical tests
- Outlier values
- Transform logarithmically the individual number of CFU/spleen,
calculate the mean Log10 CFU/spleen, and compare means by the
Fisher’s Protected Least Significant Differences test (PLSD), using a
maximum of 4 groups per comparison (including reference or
wild-type strain and, for protection studies, both the reference
vaccine and placebo control groups). The RT50 calculations
should be performed in the freely available statistical program at
[170]. - If controls do not give expected values, the assay should
be discarded (do not remove outliers).
Figure 11 Splenic growth curves of BALB/c mice infected with
several B. abortus S19 vaccine strains, from different sources.
Mice were intraperitoneally inoculated with 105 CFU/mouse of the
corresponding strain and the number of bacteria estimated in the
spleens at different times pi (adapted from [34], with permission).
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values [23,24]. After the 4th week, the CFU values in
vaccinated and unvaccinated mice decrease in parallel
usually maintaining a difference of two to three loga-
rithms. Thus, vaccine efficacy is generally analyzed
2 weeks after challenge, when the differences between
the reference-vaccinated and unvaccinated controls are
already at a maximum, and longer times do not offer a
better discrimination span with respect to protection.
Different statistical procedures for evaluating vaccine
efficacy are used. The Fisher's Protected Least Significant
Differences or the Bonferroni's tests (depending on the
number of groups compared) usually give statistically
weighted (i.e. equilibrium between alpha and beta errors)
results. In this, both reference-vaccinated and unvaccin-
ated controls act respectively as upper and lower refer-
ence limits of protection in the ANOVA test. As
indicated above, the level of protection is expressed as
log10(X/log10X) in the reference method. Reportedly, this
transformation allows better data normalization than
log10X when this value is below 1.58 [173] but in the
authors’ experience it is not necessary in most casesb.
It is necessary to emphasize that new vaccine candi-
dates as well as stocks or batches of commercial S19 and
Rev1 should be contrasted with well-standardized
Brucella reference strains applying always the appropri-
ate statistical methods to measure both virulence and ef-
ficacy [33]. Variations in S19 virulence (Figure 11) and
Rev1 efficacy [32] among different stocks have been
detected using this methodology.
Superinfection and antigen therapy
One common practice in some countries has been the
revaccination or vaccination of infected animals [174].
Since abortion tends to stop or decrease after mass
vaccination with smooth vaccines, it has been
hypothesized that vaccination of infected animals
may have some therapeutic effect. In addition,vaccinated animals cohabiting with infected flocks
may be naturally challenged and become infected
with Brucella field strains [175]. Moreover, “antigen
therapy” has been used to treat human brucellosis
and claimed to be effective in improving the clinical
status of brucellosis infected patients [3,9,176]. How-
ever, these practices are of dubious value and most
of them have been abandoned because of the un-
desirable side effects. In this regard, the mouse
model has revealed significant flaws in the claims
made on the usefulness of these practices in human
medicine.
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bacterial antigens during the acute or chronic phases do
not modify the course of Brucella infections in mice
[29,81,83]. This resembles what happens in the natural
hosts [175]. It seems that, whereas the immune response
has reached a “saturating level” in the acute and steady
chronic phases (related to an extensive Brucella reticu-
loendothelial system colonization), the declining chronic
phase resembles an immunosuppression state, an event
also observed in chronic brucellosis [4,177]. This last
phenomenon may be associated to a progressive decrease
of macrophage activation [153,177] as well as to immune
regulatory mechanisms [4,65].
The evolution of brucellosis after superinfection as a
treatment in mice is related to the virulence of the
strains involved. Macrophage reactivation has been
reported after inoculating Brucella antigens in B. abortus
S19 infected animals [178]. Similarly, B. abortus S19
reinoculation in previously S19 infected mice results in a
regression of the primary infection [153]. Nevertheless,
this apparent therapeutic effect is questionable. Indeed, a
transient reactivation of the attenuated Brucella strains
may occur. In S19 vaccinated mice, the vaccine strain
may become reactivated and increase in numbers after
inoculation with virulent Brucella, brucellin or LPS [23].
This suggests that S19 does not “saturate” the reticuloen-
dothelial system as it is the case of virulent strains.
Moreover, mice infected with attenuated brucellae are
less resistant to challenge with virulent strains than
animals already infected with virulent Brucella [179].
These competing events are not trivial, mainly in proto-
cols in which mixtures of virulent and attenuated
Brucella strains have been used as an attempt to deter-
mine the relative virulence of the former in relation to
the latter bacteria [91].
Passive transfer and immunomodulation
Passive transfer of antibodies and cells, and treatment
with cytokines and immune enhancers are widely used
methods to investigate the immune responses during
murine brucellosis (Table 2). These procedures may be
divided into five groups: i) passive transfer of antibodies;
ii) passive transfer of immune cells; iii) treatment with
cytokines or immunomodulators; iv) antibody depletion
of cytokines; and v) antibody depletion of immune cells.
Passive transfer of homologous or heterologous poly-
clonal antisera from infected or immunized animals
(syngenic, allogenic or xenogenic) protects mice against
Brucella challenge [84,98,106,107]. Using monoclonal
antibodies (Mabs), it has been established that the most
relevant targets are epitopes of N-formylperosamine
sugars of the O chain of the LPS and NH polysacchar-
ides [1] as well as some Omps like Omp31, Omp25 and
Omp16 (Table 2). No correlation between the protectionmediated by passive antibody transfer and the immuno-
globulin isotype has been recorded. Strikingly, the
efficient clearance of Brucella observed in the spleens of
B cell deficient mice (Table 1) is not reversed or
improved by passive administration of immune serum
[55]. This suggests that the control of Brucella infection
is also dependent on some B cell effectors not necessarily
related to the presence of antibodies.
Passive transfer of immune splenocytes or purified
populations of CD4+ and CD8+ T cells obtained after
4 weeks of infection [98,112] protect mice against bru-
cellosis (Table 2). As expected, a higher protection is
achieved when both immune sera and cells are trans-
ferred simultaneously [107]. Similarly, passive transfer of
xenogenic macrophages together with autologous Tγδ
cells protects mice against Brucella replication; however,
passive transfer of xonogenic macrophages alone or
macrophages with autologous unprimed T cells do not
(Table 2). In addition, the administration of cytokines
generated during the Th1 response (e.g. INF-γ and IL-
12) or the injection of immunostimulants (e.g. poly-A:U
or indomethacin), promote the elimination of Brucella in
mice. Indomethacin (used to stop suppressive actions
mediated by the secretion of cyclooxygenase-dependent
prostaglandins) does not prevent the decline in Brucella-
induced INF-γ production [113]. Similarly, IL-1α
(involved in the early activation of macrophages and
recruitment of cells) induces protection during the
acute and chronic phases of brucellosis when adminis-
tered before infection [28]. In contrast, general immu-
nossupresive agents such as corticosteroids, enhance
Brucella proliferation and avoid inflammation in the
target organs [3].
Depletion of immune cells has revealed significant but
controversial results (Table 2). For example, antibody
mediated depletion of B and NK cells barely influences
the outcome of Brucella infection. In contrast, removal
of CD8+ favors the invasion and increase of Brucella
numbers in the spleen of mice. Noticeably, antibody
mediated depletion of PMNs, CD4+ or CD25+ T cells
favors the elimination of Brucella from the target organs
in mice, suggesting some regulatory events. Indeed, these
cells may exert some suppressive regulatory action on
macrophages and dendritic cells, and perhaps on T-cyto-
toxic lymphocytes [4], all cells that constitute primary
defenses against brucellosis.
Antibody mediated depletion of INF-γ, IL-12 and
TNF-α promotes Brucella replication in mice. In con-
trast, depletion of regulatory IL-10 or IL-4 favors
Brucella elimination (Table 2). This last event may be
the result of balancing the immune response towards
Th1, and therefore, favoring the efficient elimination of
brucellae by cell mediated immunity. Depletion of CD8+
T cells results in a significant increase in Brucella
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the spleen. As expected, depletion of Tγδ cells, partici-
pating in innate immunity also favors Brucella replica-
tion. The role of TNF-α may depend upon the presence
of INF-γ early in the infection, since when TNF-α is neu-
tralized in INF-γ deficient mice there is an increase of
macrophages, NK cells and neutrophils in the spleens
[57]. These effects are in keeping with the preferential
Th1 immune response during brucellosis, as well as with
the participation of TNF-α in activating phagocytic cells,
mainly during the acute and early chronic phases.
Antibiotic treatment
The mouse model has been successfully used to evaluate
antibiotic doses, delivery, and efficacy, as well as for
studying the course of brucellosis and antibody response
during and after antibiotic treatments [159,180,181]. As
in the human disease, murine brucellosis is better treated
by a combination of doxycycline and aminoglycosides
(streptomycin or gentamicin), or rifampicin [159,182,183].
While doxycycline also exerts its killing action inside cells,
the second group preferentially acts extracellularly. Rifampi-
cin is capable of reducing the Brucella loads in the spleen of
mice, since it can penetrate inside leukocyte vacuoles. Con-
sequently, it has better intracellular activity than aminogly-
cosides [158,183]. The effectiveness of rifampicin or
gentamicin combined with doxycycline against strepto-
mycin-resistant B. melitensis Rev1 has been demonstrated
both in humans and mice [184,185]. However, treatments
with a combination of gentamicin-doxycycline seem to be
the most efficient against this vaccine strain.
The combination of doxycycline (50 mg/kg body weight/
12 h for 45 days, orally), and streptomycin (i.p., 10–20 mg/
kg body weight/l2 h, for 14 days) is the most efficient treat-
ment against brucellosis in mice. This regime, which is very
similar to that given to humans, does not cause relapses in
mice, as far as 7 months after antibiotic treatment [159].
Accordingly, 13 days after treatment, the bacterial loads in
the spleen are reduced more than three logarithms with re-
spect to untreated mice, and bacteria are not detected in
the spleen after 47 days of treatment (Figure 10). This com-
bined regime is superior to single treatments. Indeed,
regimes using only doxycycline do not completely elimin-
ate the bacteria and may cause relapses after the 30th
week of infection (Figure 10). Efforts to find substitutes
for doxycycline and alternative tetracyclines for brucel-
losis treatment have failed. Despite the good brucellicidal
action in vitro, experiments in mice using fluoroquino-
lones (moxifloxacin, gatifloxacin, ciprofloxacin and levo-
floxacin) or macrolides (erythromycin, dirithromycin or
azithromycin), have been unsuccessful [180,181,186-188].
Various protocols to evaluate intracellular delivery
of antibiotics inside the Brucella replication vacuole
have been tested in mice. Gentamicin containingmicrospheres, obtained by spray drying, reduced
significantly the splenic infection in mice after i.p. or
i.v. administration [188]. However, some mice died of
pulmonary embolism due to aggregation of the parti-
cles. Attempts to solve this were done by including
gentamicin within polymeric nanoparticles made out
of D,L-lactide-coglycolide [189]. In this model, genta-
micin-containing microspheres administrated i.v.
reduced but not eliminated the burden of B. meliten-
sis infection. Interestingly, the microsphere body
distribution was similar to that followed by Brucella
organisms, being spleen and liver the main target
organs. An alternative approach to improve antibiotic
treatment has been the inclusion of streptomycin
and doxycycline into macromolecular nanoplexes
[190]. Intravenous administration of two doses
reduced the number of B. melitensis 16 M in spleens
and livers of mice, and seemed more effective than
free drugs. Pharmacokinetics of these nanoparticles
containing antibiotics has not been studied.
Decline of antibody titers against LPS and proteins
after antibiotic treatment in human patients frequently
corresponds with successful elimination of the Brucella
[182]. In contrast, titers of antibodies against Brucella
LPS have a tendency to remain elevated in treated mice
(Figure 10). This is evident with high challenge doses
(e.g. >106 B. melitensis CFU/mouse) and with antibiotic
regimes (e.g. doxycycline or doxycycline-streptomycin)
given orally after the 3rd week of infection [159]. The
difference between mice and humans may be due to the
shorter life span of the former and/or the ability of anti-
LPS antibodies to protect mice against brucellosis
(Table 2). However, when treatment starts during the 1st
week of infection and the challenge dose is lower (<104
B. melitensis CFU/mouse), the antibody response against
Brucella cytoplasmic proteins decreases to undetectable
levels in mice [191]. This parallels the low or lack of
anti-protein responses in human patients receiving early
antibiotic treatment [192].
Concluding remarks
There are several differences and similarities between
experimental brucellosis in mice and the disease in the
natural hosts and in humans. For instance, mice are
quite resistant to Brucella infection but, in contrast to
natural hosts, do not seem to shed Brucella significantly
and the infection seems to be contained. Therefore,
horizontal transmission does not seem important in ex-
perimental murine brucellosis. In non-treated human
patients or in dolphins, brucellosis may become chronic,
causing cardiopathies, extensive bone lesions and neuro-
brucellosis, as well as other severe pathologies [9,77,129].
Strikingly, all these syndromes are seldom recorded in
infected mice when using current protocols and
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the organs and overcome the immune response). In
mice, the liver is the shock organ and the inflammatory
immune response in the spleen protects the liver from
massive Brucella invasion [14,15]. Similarly, humans also
display splenomegaly and during chronic brucellosis the
liver becomes one of the sites for Brucella replication
[3,9]. In contrast, prominent liver granuloma formation
and large splenomegaly have seldom been reported in
ruminants [130]. While active spleen hematopoiesis is a
conspicuous feature in murine brucellosis, it is a very
rare event in humans and ruminants [21]. A common
feature of murine, human and domestic animal brucel-
losis is the absence of endotoxic symptoms at the onset
of the infection, a phenomenon related to the stealthy
strategy of Brucella [4,48].
As in other mammals, the mouse giant mononuclear
placental trophoblasts are also target cells for Brucella.
The invasion of placenta occurs at specific periods in ex-
perimentally infected mice and natural hosts but with
different clinical consequences. In fact, Brucella infec-
tions occurring later in pregnancy (i.e. after the last one-
third of pregnancy) or close to delivery, induce less abor-
tions in both natural hosts and mice [135]. However,
there are fundamental differences between placental
infections in mice and in natural hosts. Mice are quite
resistant to Brucella induced abortion and abortion is
linked to a particular immune response within a narrow
window of the gestation period in which the placenta is
effectively colonized by the invading Brucella [135]. In
contrast, in bovines and small ruminants, abortion gen-
erally occurs during the last one-third of pregnancy, irre-
spectively of whether they were infected months or years
before [8,130,193]. This difference between mice and
ruminants may be related not only to the nature of
trophoblastic cells but also to placental structure [194].
For instance, in ungulates there is no transplacentary
transfer of antibodies while in rodents there is a signifi-
cant transmission of antibodies from the mother to the
fetus. This is relevant since the antibody response in
mice against Brucella could protect the fetuses. Regard-
ing the reproductive organs of male mice, Brucella
colonize the testes very early after experimental infection
[76] with invasion of the epididymis [128], a
phenomenon that resembles brucellosis in human, bo-
vine, ovine and caprine males.
The understanding of immune mechanisms during
brucellosis has been a significant contribution of the
mouse model. The furtive strategy of Brucella to over-
come the innate immunity at the onset of the infection, the
role of INF-γ and the Th1 responses in controlling brucel-
losis during the rise of adaptive immunity, have been par-
tially elucidated using the mouse model [4,48,66,103,125].
There are, however, significant discrepancies in both innateand adaptive immunity mechanisms between mice, humans
and ruminants [20,21,195,196]. For instance, mouse macro-
phages seem to be more bactericidal and less permissive
than human macrophages [66,197]. The mouse resistance
to Brucella may be also related to a higher proportion of
lymphocytes in relation to other cells such a neutrophils.
The murine C'2 and C'3 complement activities are quite
low, and the serum contains a potent inhibitor of lytic ac-
tivity precluding this function in mice. The properties of
immunoglobulin isotypes are also different in mice, bovines
and humans. Other significant variations are the absence of
defensins in mouse leukocytes, different subsets of TLR,
inducible NO synthase, the NK inhibitory receptor families
Ly49 and KIR, FcR, the B cell (BLNK, Btk, and λ5), T cell
(ZAP70 and common γ-chain) signaling pathway
components, Thy-1, γδT cells, cytokines and cytokine
receptors, Th1/Th2 differentiation, costimulatory molecule
expression and function, antigen-presenting function of
endothelial cells, chemokines and chemokine receptor
expression and the absence of granulysin in murine Tc
lymphocytes [21].
It is intriguing that various acquired or innate immune
deficiencies do not seem to alter the outcome of Brucella
infection in mice (Tables 1 and 2). For instance, neutro-
phil depletion and B cells immune deficiency seem to
favor the elimination of Brucella from the spleens of the
corresponding treated or knockout mice more readily
than what it happens in the wild type. This suggests that
complex immune regulatory and compensatory events
may take place during Brucella infection in mice [4]. It
has been proposed that the augmented bacterial
clearance in B-cell deficient mutant mice corresponds to
an increase in IFN-γ-producing T cells and a reduction
in IL-10-producing cells [55]. Similarly, in B cell deficient
jh knockout mice, bacterial clearance seems also to be
dependent on IFN-γ production but inversely related to
the levels of TGF-β at early stages of infection.
Some confusion results from the different methods
used to evaluate the immune responses in mice. The
most reliable are the classical methods that consist in: i)
determining the DTH, the amount of antibodies and
cytokines in sera by immunochemical assays; and ii) the
number and type of cells in blood and organ by micros-
copy or cytometry. In spite of their relative low sensitiv-
ity, these methods are specific and render consistent
results. The interpretation of the immune response by
ex vivo indirect assays, in which cell proliferation or
cytokines are measured in cell cultures exposed to anti-
gens, is not straightforward, particularly when cytokines
are indirectly determined by detecting transcripts.
Among other sources of variation, the immune cells har-
bor Brucella antigens and frequently live bacteria de-
pending upon the time at which cells are taken from the
infected mice (e.g. 7 to 60 days). This fact is rarely
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works. Similarly, the estimated transcripts seldom paral-
lel the quantitative measurement of proteins [195].
Therefore, it is recommended to contrast the results
obtained by indirect procedures with those generated by
direct methods.
A significant number of reports present replication and
persistence patterns of reference or type Brucella strain that
do not reproduce those established in mice. Generally, this
means that the Brucella type strain used has become atte-
nuated, and this is important source of misunderstanding,
mainly in pathogenicity and virulence studies. Other source
of confusion corresponds to the manner in which data are
expressed or presented. It is common to notice published
information schematically plotted to display “significant”
conspicuous values (e. g. bars or peaks) without including a
full virulent positive control administered at the optimal
dose that could reveal the real magnitude of the response.
Taking into account that ordinate axis can represent differ-
ent scales the risk is that the plotted values may appear sig-
nificant, when no adequate saturating control (inducing the
maximum response) is included. Similarly, in other type of
experiments, it is necessary to contrast the results obtained
with Brucella with those of unrelated infections, mitogens
or immunostimulants (e.g. Listeria, Salmonella, concanava-
line A or LPS) that generate well known saturating
responses.
Few live vaccines are able to confer adequate protection
in domestic ruminants, and subcellular vaccines or killed
bacterins are not protective enough in the natural hosts.
This is in clear contrast with many experimental results in
mice. Nevertheless, under well-standardized conditions the
mouse model is a useful tool for screening vaccines, even
though one vaccine that performs efficiently in mice may
not work in the natural host. The opposite, however, has
not been reported: vaccines that protect poorly in mice are
useless in the natural hosts [85,198,199]. In any case, for
vaccine evaluation it is always necessary to use controls vac-
cinated with the reference vaccine strains and to apply the
correct statistical tests. A summary of the general problems
and recommendations when performing experiments with
Brucella in the mouse model is presented in Table 3.
Mus musculus seems to be the second most abundant
and disperse mammalian species in the world, after
Homo sapiens. This rodent diverged from ungulates and
primates about 90 million years ago [200], probably at
the time when Brucella speciation occurred in various
animal hosts [201]. Although for many decades Brucella
organisms have been isolated in some species of Muroi-
dea, [202,203], M. musculus has not been found to be a
reservoir of Brucella. This is remarkable, taken into con-
sideration that “house mice” have shared habitat and
food with humans and domestic animals for millennia,
mainly after the domestication of crops and ruminants[204]. Thus, whereas it is clear that M. musculus consti-
tutes a valuable non-natural host for brucellosis studies,
the advantages and limitations of the model should be
properly understood within the right experimental
context.
Endnotes
aFor example, for B. abortus 544 and S19 differenti-
ation, incubate under a CO2 atmosphere (where both
strains grow) and under normal atmosphere (where only
S19 grows) and subtract the values obtained for the same
spleen dilution.
bFor a practical example, see (Additional file 1: Table S1).
Additional file
Additional file 1: Table S1. Recommended method for calculating the
level of spleen infections in mice.
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